

**This Page Is Inserted by IFW Operations
and is not a part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



68

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : C12N 15/11, 15/63, 15/82, A01N 63/00, A01H 5/00		A1	(11) International Publication Number: WO 00/68374 (43) International Publication Date: 16 November 2000 (16.11.00)
(21) International Application Number: PCT/EP00/04117 (22) International Filing Date: 8 May 2000 (08.05.00) (30) Priority Data: 09/309,038 10 May 1999 (10.05.99) US (71) Applicant (for all designated States except AT US): NOVARTIS AG [CH/CH]; Schwarzwaldallee 215, CH-4058 Basel (CH). (71) Applicant (for AT only): NOVARTIS-ERFINDUNGEN VERWALTUNGSGESELLSCHAFT M.B.H. [AT/AT]; Brunner Strasse 59, A-1230 Vienna (AT). (72) Inventors; and (75) Inventors/Applicants (for US only): HEIFETZ, Peter, Bernard [US/US]; 3916 Sturbridge Drive, Durham, NC 27713 (US). PATTON, David, Andrew [US/US]; 3506 Long Ridge Road, Durham, NC 27703 (US). LEVIN, Joshua, Zvi [US/US]; 1008 Urban Avenue, Durham, NC 27701 (US). QUE, Qiudeng [CN/US]; 108 Forest Brook Drive, Apex, NC 27502 (US). DE HAAN, Petrus, Theodorus [NL/NL]; Kruideel 34, NL-1602 GI Enkhuizen (NL). GIELEN, Johannes, Jacobus, Ludgerus [NL/FR]; 6A, impasse Manet, F-31340 Aucanville (FR).		(74) Agent: BECKER, Konrad; Novartis AG, Patent and Trademark Dept. Agribusiness, Site Rosental, CH-4002 Basel (CH). (81) Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	
(54) Title: REGULATION OF VIRAL GENE EXPRESSION			
(57) Abstract The present invention relates to methods to alter the expression of a viral gene in a cell using sense and antisense RNA fragments of the gene. The sense and antisense RNA fragments are capable of pairing and forming a double-stranded RNA molecule, thereby altering the expression of the gene. The present invention also relates to cells, plants or animals, their progeny and seeds derived thereof, obtained using a method of the present invention. Preferably, such cells, plants or animals are resistant or tolerant to viruses.			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

REGULATION OF VIRAL GENE EXPRESSION

The present invention relates to methods of altering the expression of viral genes in cells, plants or animals using sense and antisense RNA fragments of said genes, and to cells, plants or animals with altered viral gene expression obtained using the methods of the present invention. The invention particularly relates to such cells, plants or animals resistant or tolerant to viruses.

An area of deep interest is resistance or tolerance to viruses. Viruses affect most living organisms. In crops, large proportions of the harvest may be lost due to virus infections. Farm animals are also often infected by viruses and must sometimes be slaughtered to prevent spreading of the disease leading to dramatic economic consequences. Companion animals are also affected by viruses, and, finally, viruses infect humans causing a lot of suffering. Although treatments against viruses have been developed, they are very often either extremely expensive or of limited efficiency.

It is desirable to modify cells, plants or animals so that the expression of a particular viral gene is altered to create cells, plants or animals resistant or tolerant to said virus. Current methods to alter the expression of a gene usually rely upon techniques of sense or antisense suppression. Unfortunately, these methods are often variable and unpredictable in their ability to alter gene expression, and in many cases a complete disruption of the particular gene activity is not achieved.

There is therefore a long-felt but unfulfilled need for novel methods and compositions allowing one to effectively and predictably alter the expression of a viral gene to obtain cells, plants or animals with resistance or tolerance to viruses.

The present invention relates to methods of altering the expression of a viral gene in cells, plants or animals using sense and antisense RNA fragments of the gene. Importantly, such sense and antisense RNA fragments are capable of forming a double-stranded RNA molecule. Particularly, the present invention relates to methods and compositions of conferring upon a cell, plant or animal resistance or tolerance to viruses. Preferably the invention relates to methods of conferring upon a plant resistance or tolerance to viruses. The invention also preferably relates to plant cells obtained using such methods, to plants derived from such cells, to the progeny of such plants and to seeds derived from such plants. In such plant cells or plants, the alteration of the gene expression of a particular viral

gene is more effective, selective and more predictable than the alteration of the gene expression of a particular viral gene obtained using current methods known in the art.

The invention therefore provides:

A method comprising introducing into a cell a plurality of sub-sequences, e.g. RNA fragments or DNA sequences, characterized in that at least two of the sub-sequences have sense and antisense sequences of viral RNAs and are capable of forming a double-stranded RNA molecule. Preferably, the method comprises introducing into a cell an RNA which consists of a plurality of sub-sequences characterized in that at least two of the sub-sequences have the sequences of viral RNAs. Preferably, the RNA contains at least one translational stop codon located upstream of the 3' terminal sub-sequence. In another preferred embodiment, the method comprises introducing into a cell a nucleotide sequence or DNA molecule encoding expression of said RNA.

The invention therefore provides:

A method comprising introducing into a cell a sense RNA fragment of a viral target gene and an antisense RNA fragment of said target gene, wherein said sense RNA fragment and said antisense RNA fragment are capable of forming a double-stranded RNA molecule, wherein the expression of said target gene in said cell is altered. In a preferred embodiment, the target gene comprises a viral genome or a portion thereof and the cell is preferably resistant or tolerant to viruses. In a preferred embodiment, the virus is selected from the group consisting of tospoviruses, potyviruses, potexviruses, tobamoviruses, luteoviruses, cucumoviruses, bromoviruses, closteroviruses, tombusviruses and furoviruses. In another preferred embodiment, the RNA fragments comprise nucleotide sequences derived from a viral coat protein gene, a viral nucleocapsid protein gene, a viral replicase gene, a movement protein gene or portions thereof. In a further preferred embodiment, a cell is a plant cell, such as a monocotyledonous or a dicotyledonous cell. In another preferred embodiment, the RNA fragments are comprised in two different RNA molecules. In another preferred embodiment, the RNA fragments are mixed before being introduced into said cell. In another preferred embodiment, the RNA fragments are mixed before being introduced into said cell under conditions allowing them to form a double-stranded RNA molecule. In another preferred embodiment, the RNA fragments are introduced into said cell sequentially. In yet another preferred embodiment, the RNA fragments are comprised in

one RNA molecule. In such case, the RNA molecule is preferably capable of folding such that said RNA fragments comprised therein form a double-stranded RNA molecule.

The invention further provides:

A method comprising introducing into a cell a first DNA sequence capable of expressing in said cell a sense RNA fragment of a viral target gene, and a second DNA sequence capable of expressing in said cell an antisense RNA fragment of said target gene, wherein said sense RNA fragment and said antisense RNA fragment are capable of forming a double-stranded RNA molecule, wherein the expression of said viral target gene in said cell is altered. In a preferred embodiment, the target gene comprises a viral genome or a portion thereof and the cell is preferably resistant or tolerant to viruses. In a preferred embodiment, the virus is selected from the group consisting of tospoviruses, potyviruses, potexviruses, tobamoviruses, luteoviruses, cucumoviruses, bromoviruses, closteroviruses, tombusviruses and furoviruses. In another preferred embodiment, the DNA sequences comprises a nucleotide sequence derived from a viral coat protein gene, a viral nucleocapsid protein gene, a viral replicase gene, a movement protein gene or portions thereof. In a further preferred embodiment, a cell is a plant cell, such as a monocotyledonous or a dicotyledonous cell. In a preferred embodiment, the DNA sequences are stably integrated in the genome of the plant cell. In a preferred embodiment, the DNA molecule further comprises a promoter operably linked to said first or said second DNA sequence. In another preferred embodiment, the first DNA sequence and the second DNA sequence are comprised in two different, i.e. separate DNA molecules.

Alternatively, the first DNA sequence and the second DNA sequence are comprised in one DNA molecule. In this case, the first DNA sequence and the second DNA sequence are preferably comprised in the same DNA strand of said DNA molecule meaning that the sense RNA fragment and the antisense RNA fragment are comprised in one RNA molecule. Preferably, the RNA molecule is capable of folding such that said RNA fragments comprised therein form a double-stranded region. Examples of such RNA molecules comprise the inverted repeat sequence of SEQ ID NO: 13, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 25 or SEQ ID NO: 28. In another preferred embodiment, the sense RNA fragment and the antisense RNA fragment are comprised in or expressed as two RNA molecules. In this case, the first DNA sequence and the second DNA sequence are preferably operably linked to a bi-directional promoter or, alternatively, the first DNA

sequence is operably linked to a first promoter and the second DNA sequence is operably linked to a second promoter, wherein the first promoter and the second promoter are the same promoter or different promoters. In another preferred embodiment, the first DNA sequence and the second DNA sequence are comprised in complementary strands of said DNA molecule.

In yet another preferred embodiment, the first DNA sequence is the complementary DNA strand of the second DNA sequence in said DNA molecule. In this case, the DNA molecule further comprises a first promoter operably linked to said first or second DNA sequence. In a preferred embodiment, the DNA molecule further comprises a first site-specific recombination site between said first promoter and said first or second DNA sequence and a second site-specific recombination site at the 3'-end of said first DNA sequence, wherein said first and second site-specific recombination sites are capable of inverting said first or second DNA sequence between said first and second site-specific recombination sites in presence of a site-specific recombinase. In a further preferred embodiment and as a result of said inverting said first promoter is capable of expressing said second (or first, depending on which DNA sequence was originally linked to the promoter) DNA sequence. The plant cell preferably further comprises a site-specific recombinase capable of recognizing said site-specific recombination sites.

In yet another preferred embodiment, the DNA molecule further comprises a first promoter operably linked to said first DNA sequence and a second promoter operably linked to said second DNA sequence, wherein the first promoter and the second promoter comprise the same promoter or comprise different promoters.

In another preferred embodiment, the promoter in the DNA molecule comprises a native promoter of said cell. In a further preferred embodiment, the promoter is a heterologous promoter, for example a tissue specific promoter, a developmentally regulated promoter, a constitutive promoter or an inducible promoter. Optionally, the promoter is a divergent or bi-directional promoter capable of initiating transcription of DNA sequences on each side of the promoter.

In yet another preferred embodiment, the DNA sequence further comprises a linker between the DNA sequences encoding the sense and antisense RNA fragments. The linker comprises, e.g. an expression cassette comprising a functional gene, e.g. a selectable marker gene or regulatory sequences, e.g. intron processing signals.

The invention also further provides:

A cell comprising the sense and antisense RNA fragments of the present invention, wherein the expression of said viral target gene in said cell is altered by said RNA fragments. In a preferred embodiment, the cell is resistant or tolerant to viruses. In a preferred embodiment, the cell is a plant cell and the invention further provides a plant and the progeny thereof derived from the plant cell, and seeds derived from the plant.

The invention also provides:

DNA constructs comprising the DNA sequences of the present invention.

In a preferred embodiment, such a DNA construct comprises a first DNA sequence capable of expressing in a cell a sense RNA fragment of a viral genome or portion thereof and a second DNA sequence capable of expressing in said cell an antisense RNA fragment of said viral genome or portion thereof, wherein said sense RNA fragment and said antisense RNA fragment are capable of forming a double-stranded RNA molecule. In another preferred embodiment, the expression of said viral genome or portion thereof in said cell is altered. In another preferred embodiment, the cell is a plant cell. In another preferred embodiment, the virus is selected from the group consisting of tospoviruses, potyviruses, potexviruses, tobamoviruses, luteoviruses, cucumoviruses, bromoviruses, closteroviruses, tombusviruses and furoviruses. In another preferred embodiment, the DNA sequences comprises a nucleotide sequence derived from a viral coat protein gene, a viral nucleocapsid protein gene, a viral replicase gene, a movement protein gene or portions thereof. In yet another preferred embodiment, the DNA construct further comprises a promoter operably linked to said first or said second DNA sequence. In yet another preferred embodiment, the DNA construct comprises a first promoter operably linked to said first DNA sequence and a second promoter operably linked to said second DNA sequence. In yet another preferred embodiment, the DNA construct further comprises a bi-directional promoter operably linked to said first DNA sequence and said second DNA sequence.

The invention further provides:

A DNA construct comprising:

(a) a first DNA sequence capable of expressing in a cell a sense RNA fragment of a target gene and a second DNA sequence capable of expressing in said cell an antisense RNA fragment of said target gene, wherein said sense RNA fragment and said antisense RNA fragment are capable of forming a double-stranded RNA molecule, wherein said first DNA

sequence is the complementary strands of said second DNA sequence in said DNA construct,

(b) a promoter operably linked to said first or second DNA sequence,

(c) a first site-specific recombination site between said promoter and said first or second DNA sequence, and

(d) a second site-specific recombination site at the 3'-end of said first or second DNA sequence, wherein said first and second site-specific recombination sites are capable of inverting said first or second DNA sequence between said first and second site-specific recombination sites in presence of a site-specific recombinase.

In a preferred embodiment, the expression of said target gene in said cell is altered.

The invention further provides:

A DNA construct comprising:

(a) a first DNA sequence capable of expressing in a cell a sense RNA fragment of a target gene and a second DNA sequence capable of expressing in said cell an antisense RNA fragment of said target gene, wherein said sense RNA fragment and said antisense RNA fragment are capable of forming a double-stranded RNA molecule, wherein said first DNA sequence is the complementary strands of said second DNA sequence in said DNA construct,

(b) a first promoter operably linked to said first DNA sequence,

(c) a second promoter operably linked to said second DNA sequence.

In a preferred embodiment, the expression of said target gene in said cell is altered.

A "double-stranded RNA (dsRNA)" molecule comprises a sense RNA fragment of a target gene and an antisense RNA fragment of the same target gene, which both comprise nucleotide sequences complementary to one another, thereby allowing the sense and antisense RNA fragments to pair and form a double-stranded RNA molecule.

"Complementary" refers to two nucleotide sequences which comprise antiparallel nucleotide sequences capable of pairing with one another upon formation of hydrogen bonds between the complementary base residues in the antiparallel nucleotide sequences.

"Antiparallel" refers herein to two nucleotide sequences paired through hydrogen bonds between complementary base residues with phosphodiester bonds running in the 5'-3' direction in one nucleotide sequence and in the 3'-5' direction in the other nucleotide sequence.

A "target gene" is any viral gene of known function or is a gene whose function is unknown, but whose total or partial nucleotide sequence is known. A target gene is an native gene of the cell or is a heterologous gene which had previously been introduced into the cell, preferably by genetic transformation or viral infection of the cell. Preferably, the target gene is a gene in a plant cell.

A "native" gene refers to a gene which is present in the genome of the untransformed cell.

An "essential" gene is a gene encoding a protein such as e.g. a biosynthetic enzyme, receptor, signal transduction protein, structural gene product, or transport protein that is essential to the growth or survival of the cell.

To "alter" the expression of a target gene in a cell means that the level of expression of the target gene in a cell after applying the method of the present invention is different from its expression in the cell without applying the method. To alter gene expression preferably means that the expression of the target gene in the cell is reduced, preferably strongly reduced, more preferably the expression of the gene is not detectable, resulting in a knockout mutant phenotype in cells or plants or animals derived thereof.

"Isolated" is, in the context of the present invention, an isolated nucleic acid molecule that, by the hand of man, exists apart from its native environment and is therefore not a product of nature. An isolated nucleic acid molecule may exist in a purified form or may exist in a non-native environment such as, for example, a transgenic host cell.

"Expression cassette" as used herein means a DNA sequence capable of directing expression of a particular nucleotide sequence in an appropriate host cell, comprising a promoter operably linked to the nucleotide sequence of interest which is operably linked to termination signals. It also typically comprises sequences required for proper translation of the nucleotide sequence. The coding region usually codes for a protein of interest but may

also code for a functional RNA of interest, for example antisense RNA or a nontranslated RNA, in the sense or antisense direction. The expression cassette comprising the nucleotide sequence of interest may be chimeric, meaning that at least one of its components is heterologous with respect to at least one of its other components. The expression cassette may also be one which is naturally occurring but has been obtained in a recombinant form useful for heterologous expression. Typically, however, the expression cassette is heterologous with respect to the host, i.e., the particular DNA sequence of the expression cassette does not occur naturally in the host cell and must have been introduced into the host cell or an ancestor of the host cell by a transformation event. The expression of the nucleotide sequence in the expression cassette may be under the control of a constitutive promoter or of an inducible promoter which initiates transcription only when the host cell is exposed to some particular external stimulus. In the case of a multicellular organism, such as a plant, the promoter can also be specific to a particular tissue or organ or stage of development.

"Heterologous" as used herein means "of different natural origin" or represents a non-natural state. For example, if a host cell is transformed with a nucleic acid sequence derived from another organism, particularly from another species, that nucleic acid sequence is heterologous with respect to that host cell and also with respect to descendants of the host cell which carry that nucleic acid sequence. Similarly, heterologous refers to a nucleotide sequence derived from and inserted into the same natural, original cell type, but which is present in a non-natural state, e.g. a different copy number, or under the control of different regulatory elements.

In its broadest sense, the term "substantially similar", when used herein with respect to a nucleotide sequence, means a nucleotide sequence corresponding to a reference nucleotide sequence, wherein the corresponding sequence encodes a polypeptide having substantially the same structure and function as the polypeptide encoded by the reference nucleotide sequence, e.g. where only changes in amino acids not affecting the polypeptide function occur. Desirably the substantially similar nucleotide sequence encodes the polypeptide encoded by the reference nucleotide sequence. The percentage of identity between the substantially similar nucleotide sequence and the reference nucleotide sequence (number of complementary bases in the complementary sequence divided by total number of bases in the complementary sequence) desirably is at least 80%, more

desirably 85%, preferably at least 90%, more preferably at least 95%, still more preferably at least 99%.

"Regulatory elements" refer to sequences involved in conferring the expression of a nucleotide sequence. Regulatory elements comprise a promoter operably linked to the nucleotide sequence of interest and termination signals. They also typically encompass sequences required for proper translation of the nucleotide sequence.

A "plant" refers to any plant or part of a plant at any stage of development. Therein are also included cuttings, cell or tissue cultures and seeds. As used in conjunction with the present invention, the term "plant tissue" includes, but is not limited to, whole plants, plant cells, plant organs, plant seeds, protoplasts, callus, cell cultures, and any groups of plant cells organized into structural and/or functional units.

"Virus resistance or tolerance" means herein that a resistant or tolerant cell, plant or animal is either not susceptible or has reduced susceptibility to one or more viruses as compared to a sensitive cell, plant or animal. Resistance or tolerance for instance means that the usual symptoms of a virus infection are absent or reduced, or that accumulation or replication of the virus in the cell is prevented or reduced, or that movement of the virus, e.g. from cell to cell is prevented or reduced.

By "alteration of the expression of the viral genome or of a portion thereof" is typically understood that accumulation, replication or movement of the virus or a portion or component thereof, e.g. a RNA, DNA or protein of the virus, in the cell is affected.

The present invention relates to methods to regulate, i.e. alter the expression of a viral gene in cells, plants or animals. Commonly available methods to regulate the expression of a gene in cells, plants or animals lack predictability and show variability depending upon which gene is to be regulated. The present method alleviates these problems and provides for reproducible and efficacious regulation of a gene in cells, plants or animals.

The gene the expression of which is regulated is a viral genome or a portion thereof. In a preferred embodiment, a cell is an eukaryotic cell, more preferably a plant cell, such as a

monocotyledonous or a dicotyledonous cell, or an animal cell e.g. from a mammal, e.g. a human, a bovine, an ovine, a porcine, a feline or a canine, or from an avian.

The present invention utilizes a sense RNA fragment and an antisense RNA fragment of a viral target gene to alter the expression of the gene in a cell. In a first embodiment, the invention provides a method comprising introducing into a cell a sense RNA fragment of a target gene and an antisense RNA fragment of said target gene, wherein said sense RNA fragment and said antisense RNA fragment are capable of forming a double-stranded RNA molecule, wherein the expression of said target gene in said cell is altered. The RNA fragments are introduced in the cells by different transformation methods such as particle bombardment or PEG-mediated transformation or electroporation. In another preferred embodiment, other techniques, such as microinjection of the RNA fragments, are used. In a preferred embodiment, the RNA fragments are comprised in two different RNA molecules. In this case, the RNA fragments are mixed before being introduced into said cell, e.g. under conditions allowing them to form a double-stranded RNA molecule. In another preferred embodiment, the RNA fragments are introduced into said cell sequentially. Preferably, the time interval between the introduction of each of the RNA molecules is short, preferably less than one hour. In yet another embodiment, the RNA fragments are comprised in one RNA molecule. By using one single RNA molecule the two complementary RNA fragments are in close proximity such that pairing and is favored. In such case, the RNA molecule is preferably capable of folding such that said RNA fragments comprised therein form a double-stranded region. In this case, the complementary parts of the RNA fragments recognize one another, pair with each other and form the double-stranded RNA molecule. In a preferred embodiment, the RNA fragments are incubated under conditions allowing them to form a double-stranded RNA molecule prior to introduction into the cell. In yet another embodiment, the RNA molecule comprises a linker between the sense RNA fragment and the antisense RNA fragment. The linker preferably comprises a RNA sequence encoded by an expression cassette comprising a functional gene, e.g. a selectable marker gene. In another embodiment, the linker comprises a RNA sequence encoded by regulatory sequences, which e.g. comprise intron processing signals. In a further embodiment, the present invention provides a method of altering the expression of a viral genome comprising introducing into a cell a first DNA sequence capable of expressing in said cell a sense RNA fragment of said viral genome and a second DNA sequence capable of expressing in said cell an antisense RNA fragment of said viral genome, wherein said sense RNA fragment and said antisense RNA fragment are capable

of forming a double-stranded RNA molecule. In a preferred embodiment, the first DNA sequence and the second DNA sequence are stably integrated in the genome of the cell. In another preferred embodiment, the DNA sequences are comprised in two different DNA molecules. In another preferred embodiment, the DNA sequences are comprised in one DNA molecule. In such case, the DNA molecule preferably encodes a single RNA molecule which comprises the sense and antisense RNA fragments. By using one single RNA molecule the two complementary RNA fragments are in close proximity such that pairing and is favored. The DNA molecule encodes two separate RNA molecules, e.g. one RNA molecule comprising a sense RNA fragment and one RNA molecule comprising an antisense RNA fragment. The single RNA molecule or the two distinct RNA molecules are preferably capable of folding such that said RNA fragments comprised therein form a double-stranded region, in which the complementary parts of the RNA fragments recognize one another, pair with each other and form the double-stranded RNA molecule.

In one embodiment, the single DNA molecule or each of the two distinct DNA molecules comprises a promoter operably linked to said DNA sequences. In a preferred embodiment, the promoter in the DNA sequence comprises a native plant promoter or the natural promoter of said viral gene to be inactivated, in order to insure that the double-stranded RNA is expressed in the same tissues and at the same time in development as the viral target gene. In another embodiment the promoter is a heterologous promoter, for example a tissue specific promoter, a developmentally regulated promoter, a constitutive promoter or an inducible promoter.

In yet another embodiment, the DNA sequence comprises a linker between the DNA sequences encoding said two complementary RNA fragments. The linker preferably comprises an expression cassette comprising a functional gene, e.g. a selectable marker gene. In another embodiment, the linker comprises regulatory sequences, which e.g. comprise intron processing signals.

DNA molecules of the present invention are transformed into cells using methods well-known in the art or described below. The present invention also provides a DNA construct comprising DNA sequences of the present invention, a recombinant vector comprising such DNA constructs and a composition comprising DNA sequences of the present invention. In the present invention the complementary region between the sense and antisense RNA fragments is desirably at least 15 nucleotides long, more desirably at least 50 nucleotides long, and preferably at least 500 bp long. Preferably, the complementary region is less than 5 kb and more preferably less than 2 kb. In one particular embodiment the complementary

region between the sense and antisense RNA fragments comprises the coding region of the target gene. In another preferred embodiment, the complementary region comprises untranslated regions (UTR) of the target gene, e.g. 5' UTR or 3' UTR. In yet another preferred embodiment, a DNA sequence encoding a sense or antisense RNA fragment of the present invention is derived from a c-DNA molecule or comprises regulatory elements of the viral target gene whose expression is to be altered, such as promoter or termination signals.

In another preferred embodiment, the complementary region between the sense and antisense RNA fragments is identical to the corresponding sequence of the gene whose expression is altered. In another preferred embodiment, the complementary region between the sense and antisense RNA fragments is substantially similar to the corresponding sequence of the gene whose expression is altered and is still capable of altering the expression of the gene. In this case, the complementary region is desirably at least 50% identical to the corresponding sequence of the gene whose expression is altered more desirably at least 70% identical, preferably at least 90% identical, more preferably at least 95% identical. Thereby, using a single double-stranded RNA molecule allows to alter the expression of a single gene or of a plurality of genes, the single gene comprising sequences identical to the double-stranded RNA or being substantially similar to the double-stranded RNA.

In another preferred embodiment, the complementary region between the sense and antisense RNA fragments does not contain any mismatch between the sense and antisense RNA fragments. In another preferred embodiment, the complementary region between the sense and antisense RNA fragments comprises at least one mismatch between the sense and antisense RNA fragments, and the two RNA fragments are still capable of pairing and forming a double-stranded RNA molecule, thereby altering the expression of the gene.

Desirably, there is less than 50% mismatch between the sense and antisense RNA fragments in the complementary region, more desirably less than 30% mismatch, preferably less than 20% mismatch, more preferably less than 10% mismatch, yet more preferably less than 5 % mismatch.

Resistance or Tolerance to Viruses

The present invention results in cells, animals or plants which are virus resistant or tolerant. Viruses controlled using the present invention comprise but are not limited to dsDNA viruses, dsRNA viruses, plus-strand and minus-strand ssRNA viruses, ambisense RNA

viruses and retroviruses. Preferably controlled are plant viruses, such as astroviruses (e.g. tomato spotted wilt virus abbreviated TSWV), potyviruses (e.g. turnip mosaic virus abbreviated TuMV, lettuce mosaic virus abbreviated LMV, water melon mosaic virus II abbreviated WMVII, Zucchini yellow mosaic virus abbreviated ZYMV, potato virus Y abbreviated PVY, and papaya ringspot virus abbreviated PRSV), potexviruses, tobamoviruses (e.g. pepper mild mottle virus abbreviated PMMV, and tomato mosaic virus abbreviated ToMV), luteoviruses (e.g. beet western yellows virus abbreviated BWYV, and beet mild yellowing virus abbreviated BMV), cucumoviruses (e.g. cucumber mosaic virus abbreviated CMV), geminiviruses (e.g. tomato yellow leafcurl virus abbreviated TYLCV), caulimoviruses (e.g. Cauliflower mosaic virus abbreviated CaMV), bromoviruses, closteroviruses, tombusviruses and furoviruses (e.g. beet necrotic yellow vein virus abbreviated BNYSV). Additional classes of viruses which can be controlled using the present invention are described in Zacher et al. (1995) *Journal of General Virology*, 76: 231-247 and in Martelli (1992) *Plant Disease*, 76: 436-441. Preferred DNA sequences of a viral genome to achieve virus control correspond to regions of the genes encoding viral coat proteins, viral nucleocapsid proteins, viral replicases, movement proteins and the like. Further nucleotide sequences useful to control virus genome expression are described in WO 95/09920. Preferred DNA sequences may include portions of the viral genome not translated into proteins, e.g. 5' or 3' untranslated regions.

Preferably, a method of the present invention leads to resistance or tolerance to a broad-spectrum of viruses. For example, a method of the present invention leads to resistance or tolerance to the virus encoded by the viral genome and other viruses in the same virus class, group or genus. Alternatively, a method of the present invention leads to resistance or tolerance to the virus encoded by the viral genome and other isolates of the same virus. Also, a method of the present invention leads to resistance or tolerance to the virus encoded by the viral genome and other viruses in the same virus group or genus in different species, preferably in related species, preferably species in which such viruses exist. Optionally, more than one pair, i.e. at least two pairs of sense and antisense RNA fragments which are capable of forming a dsRNA are used. Such pairs are for example derived from the same viral genome, but from different portions of the same viral genome. Alternatively, such pairs are derived from different viral genomes. Thus, resistance or tolerance to different virus classes, groups or genera is achieved using the present invention.

Plant cells and plants derived thereof, which are virus resistant or tolerant are preferably dicotyledonous plants. Methods to confer resistance or tolerance to furoviruses (see e.g. Rush and Heidel (1995) Plant Disease 79: 868-875) in sugar beet and canola are disclosed in the present invention and described in further detail for BNYVV, the causal agent of rhizomania (crazy roots) in sugar-beet, in Example 9. Methods to confer resistance or tolerance to "virus yellow" (see e.g. CRC Handbook on Disease of Sugar Beet, Volume II, pp. 35-52) such as BMV and beet western yellows virus (BWYV) that infect sugar beet and oilseed rape, respectively, are described in further detail in Example 8.

Methods of the present invention also confer tolerance or resistance to viruses in monocotyledonous plants. For example, using the teachings of the present invention and of US patent 5,569,828 tolerance or resistance to Maize chlorotic dwarf virus is obtained. Similarly, using the teachings of the present invention and of US patent 5,428,144 tolerance or resistance to Maize dwarf mosaic virus is achieved.

Plant Transformation Technology

DNA molecules of the present invention are incorporated in plant or bacterial cells using conventional recombinant DNA technology. Generally, a DNA molecule of the present invention is comprised in a transformation vector. A large number of such vector systems known in the art are used, such as plasmids, bacteriophage viruses and other modified viruses. The components of the expression system are also modified, e.g. to increase expression of the sense and antisense RNA fragments. For example, truncated sequences, nucleotide substitutions or other modifications are employed. Expression systems known in the art are used to transform virtually any crop plant cell under suitable conditions. A transgene comprising a DNA molecule of the present invention is preferably stably transformed and integrated into the genome of the host cells. In another preferred embodiment, the transgene comprising a DNA molecule of the present invention is located on a self-replicating vector. Examples of self-replicating vectors are viruses, in particular gemini viruses. Transformed cells are preferably regenerated into whole plants.

Plants transformed in accordance with the present invention may be monocots or dicots and include, but are not limited to, maize, wheat, barley, rye, sweet potato, bean, pea, chicory, lettuce, cabbage, cauliflower, broccoli, turnip, radish, spinach, asparagus, onion, garlic, pepper, celery, squash, pumpkin, hemp, zucchini, apple, pear, quince, melon, plum, cherry, peach, nectarine, apricot, strawberry, grape, raspberry, blackberry, pineapple, avocado, papaya, mango, banana, soybean, tomato, sorghum, sugarcane, sugarbeet, sunflower,

rapeseed, clover, tobacco, carrot, cotton, alfalfa, rice, potato, eggplant, cucumber, Arabidopsis, and woody plants such as coniferous and deciduous trees. Once a desired nucleotide sequence has been transformed into a particular plant species, it may be propagated in that species or moved into other varieties of the same species, particularly including commercial varieties, using traditional breeding techniques.

A. Requirements for Construction of Plant Expression Cassettes

Gene sequences intended for expression in transgenic plants are first assembled in expression cassettes behind a suitable promoter expressible in plants. The expression cassettes may also comprise any further sequences required or selected for the expression of the transgene. Such sequences include e.g., but are not restricted to, transcription terminators, extraneous sequences to enhance expression such as introns, viral sequences, and sequences intended for the targeting of the gene product to specific organelles and cell compartments. These expression cassettes can then be easily transferred to the plant transformation vectors described *infra*. The following is a description of various components of typical expression cassettes.

1. Promoters

The selection of the promoter used in expression cassettes determine the spatial and temporal expression pattern of the transgene in the transgenic plant. Selected promoters express transgenes in specific cell types (such as leaf epidermal cells, mesophyll cells, root cortex cells) or in specific tissues or organs (roots, leaves or flowers, for example) and the selection reflects the desired location of accumulation of the gene product. Alternatively, the selected promoter drives expression of the gene under various inducing conditions. Promoters vary in their strength, i.e., ability to promote transcription. Depending upon the host cell system utilized, any one of a number of suitable promoters known in the art is used. For example, for constitutive expression, the CaMV 35S promoter, the rice actin promoter, or the ubiquitin promoter are used. For example, for regulatable expression, the chemically inducible PR-1 promoter from tobacco or *Arabidopsis* is used (*see, e.g.*, U.S. Patent No. 5,689,044).

A preferred category of promoters is that which is wound inducible. Numerous promoters have been described which are expressed at wound sites. Preferred promoters of this kind include those described by Stanford *et al.* Mol. Gen. Genet. 215: 200-208 (1989), Xu *et al.* Plant Molec. Biol. 22: 573-588 (1993), Logemann *et al.* Plant Cell 1: 151-158 (1989),

Rohrmeier & Lehle, *Plant Molec. Biol.* 22: 783-792 (1993), Firek *et al.* *Plant Molec. Biol.* 22: 129-142 (1993), and Warner *et al.* *Plant J.* 3: 191-201 (1993).

Preferred tissue specific expression patterns include green tissue specific, root specific, stem specific, and flower specific. Promoters suitable for expression in green tissue include many which regulate genes involved in photosynthesis, and many of these have been cloned from both monocotyledons and dicotyledons. A preferred promoter is the maize PEPC promoter from the phosphoenol carboxylase gene (Hudspeth & Grula, *Plant Molec. Biol.* 12: 579-589 (1989)). A preferred promoter for root specific expression is that described by de Framond (*FEBS* 290: 103-106 (1991); EP 0 452 269 and a further preferred root-specific promoter is that from the T-1 gene provided by this invention. A preferred stem specific promoter is that described in US patent 5,625,136 and which drives expression of the maize *trpA* gene.

Preferred embodiments of the invention are transgenic plants expressing nucleotide sequence in a root-specific fashion. Further preferred embodiments are transgenic plants expressing the nucleotide sequence in a wound-inducible or pathogen infection-inducible manner.

2. Transcriptional Terminators

A variety of transcriptional terminators are available for use in expression cassettes. These are responsible for the termination of transcription beyond the transgene and its correct polyadenylation. Appropriate transcriptional terminators are those that are known to function in plants and include the CaMV 35S terminator, the *tm1* terminator, the nopaline synthase terminator and the pea *rbcs* E9 terminator. These are used in both monocotyledonous and dicotyledonous plants.

3. Sequences for the Enhancement or Regulation of Expression

Numerous sequences have been found to enhance gene expression from within the transcriptional unit and these sequences can be used in conjunction with the genes of this invention to increase their expression in transgenic plants. For example, various intron sequences such as introns of the maize *Adh1* gene have been shown to enhance expression, particularly in monocotyledonous cells. In addition, a number of non-translated leader sequences derived from viruses are also known to enhance expression, and these are particularly effective in dicotyledonous cells.

4. Coding Sequence Optimization

The coding sequence of the selected gene may be genetically engineered by altering the coding sequence for optimal expression in the crop species of interest. Methods for modifying coding sequences to achieve optimal expression in a particular crop species are well known (see, e.g. Perlak *et al.*, *Proc. Natl. Acad. Sci. USA* 88: 3324 (1991); and Koziel *et al.*, *Bio/technol.* 11: 194 (1993)).

In another preferred embodiment, a DNA molecule of the present invention is directly transformed into the plastid genome. Plastid transformation technology is extensively described in U.S. Patent Nos. 5,451,513, 5,545,817, and 5,545,818, in PCT application no. WO 95/16783, and in McBride *et al.* (1994) *Proc. Natl. Acad. Sci. USA* 91, 7301-7305. The basic technique for chloroplast transformation involves introducing regions of cloned plastid DNA flanking a selectable marker together with the gene of interest into a suitable target tissue, e.g., using biolistics or protoplast transformation (e.g., calcium chloride or PEG mediated transformation). The 1 to 1.5 kb flanking regions, termed targeting sequences, facilitate homologous recombination with the plastid genome and thus allow the replacement or modification of specific regions of the plastome. Initially, point mutations in the chloroplast 16S rRNA and rps12 genes conferring resistance to spectinomycin and/or streptomycin are utilized as selectable markers for transformation (Svab, Z., Hajdukiewicz, P., and Maliga, P. (1990) *Proc. Natl. Acad. Sci. USA* 87, 8526-8530; Staub, J. M., and Maliga, P. (1992) *Plant Cell* 4, 39-45). The presence of cloning sites between these markers allowed creation of a plastid targeting vector for introduction of foreign DNA molecules (Staub, J.M., and Maliga, P. (1993) *EMBO J.* 12, 601-606). Substantial increases in transformation frequency are obtained by replacement of the recessive rRNA or r-protein antibiotic resistance genes with a dominant selectable marker, the bacterial *aadA* gene encoding the spectinomycin-detoxifying enzyme aminoglycoside-3'-adenyltransferase (Svab, Z., and Maliga, P. (1993) *Proc. Natl. Acad. Sci. USA* 90, 913-917). Previously, this marker had been used successfully for high-frequency transformation of the plastid genome of the green alga *Chlamydomonas reinhardtii* (Goldschmidt-Clermont, M. (1991) *Nucl. Acids Res.* 19: 4083-4089). Other selectable markers useful for plastid transformation are known in the art and encompassed within the scope of the invention.

Plastid expression, in which genes are inserted by homologous recombination into the several thousand copies of the circular plastid genome present in each plant cell. In a preferred embodiment, a DNA of the present invention is inserted into a plastid targeting vector and transformed into the plastid genome of a desired plant host. Plants homoplasmic

for plastid genomes containing the DNA molecule of the present invention are obtained, and are preferentially capable of high expression of the DNA molecule. Preferably, sense and antisense RNA fragments encoded by the DNA molecule are capable of pairing and of forming a double-stranded RNA molecules in plant plastids to alter the expression of plastid genes. In a preferred embodiment, the sense and antisense fragments do not comprise any mismatch in the complementary region. In another preferred embodiment, the sense and antisense fragments comprise at least one mismatch in the complementary region. In this case, the DNA sequences in the DNA molecule encoding the RNA fragments are not capable of recombining with each other.

B. Construction of Plant Transformation Vectors

Numerous transformation vectors available for plant transformation are known to those of ordinary skill in the plant transformation arts, and the genes pertinent to this invention can be used in conjunction with any such vectors. The selection of vector depends upon the preferred transformation technique and the target species for transformation. For certain target species, different antibiotic or herbicide selection markers are preferred. Selection markers used routinely in transformation include the *nptII* gene, which confers resistance to kanamycin and related antibiotics (Messing & Vierra. *Gene* 19: 259-268 (1982); Bevan et al., *Nature* 304:184-187 (1983)), the *bar* gene, which confers resistance to the herbicide phosphinothricin (White et al., *Nucl. Acids Res* 18: 1062 (1990), Spencer et al. *Theor. Appl. Genet* 79: 625-631 (1990)), the *hph* gene, which confers resistance to the antibiotic hygromycin (Blochinger & Diggelmann, *Mol Cell Biol* 4: 2929-2931), and the *dhfr* gene, which confers resistance to methatrexate (Bourouis et al., *EMBO J.* 2(7): 1099-1104 (1983)), and the EPSPS gene, which confers resistance to glyphosate (U.S. Patent Nos. 4,940,935 and 5,188,642).

1. Vectors Suitable for *Agrobacterium* Transformation

Many vectors are available for transformation using *Agrobacterium tumefaciens*. These typically carry at least one T-DNA border sequence and include vectors such as pBIN19 (Bevan, *Nucl. Acids Res.* (1984)) and pXYZ. Typical vectors suitable for *Agrobacterium* transformation include the binary vectors pCIB200 and pCIB2001, as well as the binary vector pCIB10 and hygromycin selection derivatives thereof. (See, for example, U.S. Patent No. 5,639,949).

2. Vectors Suitable for non-*Agrobacterium* Transformation

Transformation without the use of *Agrobacterium tumefaciens* circumvents the requirement for T-DNA sequences in the chosen transformation vector and consequently vectors lacking these sequences are utilized in addition to vectors such as the ones described above which contain T-DNA sequences. Transformation techniques that do not rely on *Agrobacterium* include transformation via particle bombardment, protoplast uptake (e.g. PEG and electroporation) and microinjection. The choice of vector depends largely on the preferred selection for the species being transformed. Typical vectors suitable for non-*Agrobacterium* transformation include pCIB3064, pSOG19, and pSOG35. (See, for example, U.S. Patent No. 5,639,949).

C. Transformation Techniques

Once the DNA sequence of interest is cloned into an expression system, it is transformed into a plant cell. Methods for transformation and regeneration of plants are well known in the art. For example, Ti plasmid vectors have been utilized for the delivery of foreign DNA, as well as direct DNA uptake, liposomes, electroporation, micro-injection, and microprojectiles. In addition, bacteria from the genus *Agrobacterium* can be utilized to transform plant cells.

Transformation techniques for dicotyledons are well known in the art and include *Agrobacterium*-based techniques and techniques that do not require *Agrobacterium*. Non-*Agrobacterium* techniques involve the uptake of exogenous genetic material directly by protoplasts or cells. This is accomplished by PEG or electroporation mediated uptake, particle bombardment-mediated delivery, or microinjection. In each case the transformed cells are regenerated to whole plants using standard techniques known in the art.

Transformation of most monocotyledon species has now also become routine. Preferred techniques include direct gene transfer into protoplasts using PEG or electroporation techniques, particle bombardment into callus tissue, as well as *Agrobacterium*-mediated transformation.

The invention will be further described by reference to the following detailed examples. These examples are provided for purposes of illustration only, and are not intended to be limiting unless otherwise specified.

EXAMPLES

Standard recombinant DNA and molecular cloning techniques used here are well known in the art and are described by Sambrook, *et al.*, Molecular Cloning, eds., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY (1989) and by T.J. Silhavy, M.L. Berman, and L.W. Enquist, Experiments with Gene Fusions, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY (1984) and by Ausubel, F.M. *et al.*, Current Protocols in Molecular Biology, pub. by Greene Publishing Assoc. and Wiley-Interscience (1987).

Example 1: Regulation of the Expression of a Luciferase GeneConstruction of a chimeric DNA molecule encoding a luciferase RNA duplex

A 738 bp "sense" oriented fragment of the firefly luciferase gene from plasmid pLuc+ (Promega) is amplified from pPH108 plasmid DNA using oligonucleotide primers ds_Luc1 (5' -CGC GGA TCC TGG AAG ACG CCA AAA ACA-3', SEQ ID NO:1; *Bam*HI restriction site underlined) and ds_Luc2 (5' -CGG AAG CTT AGG CTC GCC TAA TCG CAG TAT CCG GAA TG-3', SEQ ID NO:2; *Hind*III restriction site underlined). TurboPfu thermostable DNA polymerase (Stratagene) is used in 50 ul reactions according to the manufacturers protocol with five cycles of 95°C / 1 min, 55°C / 1.5 min, 72°C / 2 min followed by twenty five cycles of 95°C / 1 min, 72°C / 3.5 min. In a similar manner a 737 bp "antisense" oriented fragment of the firefly luciferase gene from plasmid pLuc+ is amplified by PCR from pPH108 plasmid DNA using oligonucleotide primers ds_Luc3 (5' -CGG TCT AGA GGA AGA CGC CAA AAA CAT A-3', SEQ ID NO:3; *Xba*I restriction site underlined) and ds_Luc2 (5' -CGG AAG CTT AGG CTC GCC TAA TCG CAG TAT CCG GAA TG-3', SEQ ID NO: 2; *Hind*III restriction site underlined). The resulting DNA fragments are purified by electrophoresis through a 1% Tris-acetate gel made from low-melting point agarose (FMC) followed by phenol-chloroform extraction of the excised gel slices containing the PCR products. DNA from the sense product (ds_Luc1/2) is digested with *Bam*HI and *Hind*III and DNA from the antisense product (ds_Luc3/2) is digested with *Xba*I and *Hind*III according to standard methods (restriction enzymes were obtained from New England Biolabs). The resulting sticky-ended DNA fragments are gel purified as described above. A DNA fragment containing the *mas* 1' promoter (Velten et al. (19984) EMBO J. 3: 2723-2730) is obtained by digesting plasmid CSA104 with *Eco*RI and *Hinc*II and purifying a 564 bp DNA fragment. This fragment is redigested with *Bam*HI and the 484 bp *Eco*RI – *Bam*HI sub-

fragment containing the *mas* 1' promoter isolated and gel purified. In order to construct plasmid pPH169, DNA from cloning vector pLitmus29 (New England Biolabs) is digested with *EcoRI* and *XbaI*, and the isolated fragment is ligated in a four-way reaction using T4 DNA ligase (New England Biolabs) to the *mas* 1' promoter *EcoRI* – *BamHI* fragment and the sense (*BamHI* – *HindIII*) and antisense (*HindIII* – *XbaI*) ds_Luc luciferase gene fragments. In order to construct binary vector pPH170 for *Agrobacterium*-mediated plant transformation with the ds_Luc1/2/3 RNA duplex construct, DNA from binary plasmid pSGCHC1 carrying a kanamycin resistance gene for bacterial selection and a hygromycin resistance gene for transgenic plant selection is digested with *EcoRI* and *XbaI*. The resulting 11.6 kb isolated fragment from pSGCHC1 is ligated in a four-way reaction using T4 DNA ligase (New England Biolabs) to the *mas* 1' promoter *EcoRI* – *BamHI* fragment and the sense (*BamHI* – *HindIII*) and antisense (*HindIII* – *XbaI*) ds_Luc luciferase gene fragments.

Transformation of *Agrobacterium* and Vacuum-infiltration of *Arabidopsis* plants

Plasmids pPH170 is introduced into *Agrobacterium tumefaciens* GV3101 by electroporation and transformed colonies selected and amplified. Four to five week old plants of *Arabidopsis thaliana* mutant lines expressing luciferase either constitutively (UBQ3 promoter (Norris et al. (1993) PMB 21: 895-906) / UBQ3 + CaMV 35S 5' UTR/luc+; *pPH108*) or inducibly (*Arabidopsis* PR-1 promoter/luc+; *pPH135*, line 6E) are vacuum infiltrated with *Agrobacterium* clones carrying the pPH170 binary T-DNA vector. Transformed plants are co-selected on hygromycin and kanamycin and grown under controlled phytotron conditions for determination of luciferase activity. In addition, luciferase activity in the *pPH135-6E* background is assessed 48 hr after induction with BTH (BTH treatment essentially as described in Lawton et al. Plant J. 10: 71-82). Luciferase activity is quantified using a luminescence-based assay in tissue extracts following the addition of luciferin substrate. Luciferase activity is also monitored *in planta* using a CCD-cooled video imaging system (Hamamatsu).

Example 2: Regulation of the Expression of the *Arabidopsis* GL1 Gene

The GL1 gene encodes a *myb*-like transcription factor that is required for initiation of normal trichome (leaf hair) formation (Oppenheimer et al. (1991) Cell 67: 483-493). Knock out of GL1 expression early in development results in plants lacking trichomes. The knockout phenotype is easy to identify in young seedlings and is not lethal. Three vectors for constitutive expression and three vectors for Gal4CI-regulated expression are constructed.

The three different vectors to test for each promoter are sense (+) expression, antisense (-) expression, and duplex (+/-) RNA expression of a GL1 gene fragment. The (+) and (-) vectors are controls to compare for their effect on expression of GL1. In each case a 5' fragment from bases #739 to #1781 of the GL1 sequence (GenBank Accession M79448) are used for vector construction.

Gal4CI-regulated Expression

The GL1 gene fragments is cloned into the crossing-inducible vector construct pJG304-1 as *NcoI*-*SacI* fragments. Plasmid pJG304 is derived from pBSSK+. Plasmid pBS SK+ (Stratagene, LaJolla, CA) is linearized with *SacI*, treated with mung bean nuclease to remove the *SacI* site, and re-ligated with T4 ligase to make pJG201. The 10XGAL4 consensus binding site/CaMV 35S minimal promoter/GUS gene/CaMV terminator cassette is removed from pAT71 with *KpnI* and cloned into the *KpnI* site of pJG201 to make pJG304. Plasmid pJG304 is partially digested with restriction endonuclease *Asp718* to isolate a full-length linear fragment. This fragment is ligated with a molar excess of the 22 base oligonucleotide JG-L (5' -GTA CCT CGA G TC TAG ACT CGA G-3', SEQ ID NO: 4). Restriction analysis is used to identify a clone with this linker inserted 5' to the GAL4 DNA binding site, and this plasmid is designated pJG304DXhoI.

The *NcoI* and *SacI* sites are added to the ends of (+) and (-) fragments by synthesizing PCR primers with the appropriate restriction sites to the 5' termini. The (+) GL1 fragment is produced by first producing two fragment : a (+) fragment with the *NcoI* site at the 5' terminus and a *HindIII* site at the 3' terminus and a (-) fragment with a *HindIII* site at the 5' terminus and a *SacI* site at the 3' terminus. The duplex unit is produced by ligation of the resulting fragments at the *EcoRI* site. The expression unit contains the Gal4 DNA binding domain, followed by a minimal TATA sequence, and the GL1 gene fragment oriented either (+), (-) or (+/-).

Constitutive Expression

The *mas 1'* promoter of mannopine synthase from *Agrobacterium*(ref), a relatively strong and constitutive in dicot plants is used. As above, the GL (+), (-), and (+/-) fragments are ligated behind the 1' promoter in pBluescript. The three different expression cassettes are ligated into pCIB200 as *EcoRI/SalI* fragments (Uknes et al. (1993) Plant Cell 5: 159-169).

Example 3: Regulation of the Expression of the Cystathionine Beta Lyase Gene

The Cystathionine Beta Lyase (CBL) Gene encodes a step in the methionine biosynthesis pathway. The effect of the regulation of its expression in plants is tested using sense and antisense constructs, and double-stranded RNA constructs.

Antisense construct: binary BASTA vector pJG261 is used containing a fragment from the pJG304DXhoI vector with an insertion of part of the CBL gene in an antisense orientation (nucleotides #13-1159, Genbank accession #L40511).

Sense construct: same as antisense construct, except the CBL fragment is in the opposite orientation. This construct contains the ATG start codon and most of the CBL ORF and serves as a control for regulation of the expression of the CBL gene.

Double-stranded RNA construct: A CBL gene fragment (#13-1159) in the sense orientation is inserted into the *Sall* site of vector pJG304-1 downstream of the antisense orientation version of the CBL gene. A linker of about 10 bp is present between the two copies of CBL.

Example 4: Requirements for Construction of Plant Expression Cassettes

Gene sequences intended for expression in transgenic plants are firstly assembled in expression cassettes behind a suitable promoter and upstream of a suitable transcription terminator. All requirement for constructions of plant expression cassettes apply to the DNA molecules of the present invention and are carried out using techniques well-known in the art.

Promoter Selection

The selection of promoter used in expression cassettes determines the spatial and temporal expression pattern of the DNA molecule in the transgenic plant. Selected promoters express DNA molecule in specific cell types (such as leaf epidermal cells, mesophyll cells, root cortex cells) or in specific tissues or organs (roots, leaves or flowers, for example) and this selection reflects the desired location of biosynthesis of a RNA fragment encoded by the DNA molecule. Alternatively, the selected promoter may drive expression of the DNA molecule under a light-induced or other temporally regulated promoter. A further alternative is that the selected promoter be chemically regulated. This provides the possibility of

inducing the expression of the DNA molecule only when desired and caused by treatment with a chemical inducer.

Transcriptional Terminators

A variety of transcriptional terminators are available for use in expression cassettes. These are responsible for the termination of transcription and, preferably, correct polyadenylation. Appropriate transcriptional terminators and those which are known to function in plants and include the CaMV 35S terminator, the *tm1* terminator, the nopaline synthase terminator, the pea *rbcs* E9 terminator. These can be used in both monocotyledons and dicotyledons.

Sequences for the Enhancement or Regulation of Expression

Numerous sequences have been found to enhance gene expression from within the transcriptional unit and these sequences can be used in conjunction with the DNA molecule of this invention to increase its expression in transgenic plants.

Various intron sequences have been shown to enhance expression, particularly in monocotyledonous cells. For example, the introns of the maize *Adh1* gene have been found to significantly enhance the expression of the wild-type gene under its cognate promoter when introduced into maize cells. Intron 1 is found to be particularly effective and enhanced expression in fusion constructs with the chloramphenicol acetyltransferase gene (Callis *et al.*, *Genes Devel* **1**: 1183-1200 (1987)). In the same experimental system, the intron from the maize *bronze1* gene had a similar effect in enhancing expression (Callis *et al.*, *supra*). Intron sequences have been routinely incorporated into plant transformation vectors, typically within the non-translated leader.

A number of non-translated leader sequences derived from viruses are also known to enhance expression, and these are particularly effective in dicotyledonous cells.

Specifically, leader sequences from Tobacco Mosaic Virus (TMV, the "Ω-sequence"), Maize Chlorotic Mottle Virus (MCMV), and Alfalfa Mosaic Virus (AMV) have been shown to be effective in enhancing expression (*e.g.* Gallie *et al.* *Nucl. Acids Res.* **15**: 8693-8711 (1987); Skuzeski *et al.* *Plant Molec. Biol.* **15**: 65-79 (1990)).

Example 5: Examples of Expression Cassette Construction

The present invention encompasses the expression of a DNA molecule of the present invention under the regulation of any promoter which is expressible in plants, regardless of the origin of the promoter. Therefore the DNA molecule is inserted into any of the

expression cassette using techniques well-known in the art. These expression cassettes can then be easily transferred to the plant transformation vectors described below. Furthermore, the invention also encompasses the use of any plant-expressible promoter in conjunction with any further sequences required or selected for the expression of the DNA molecule. Such sequences include, but are not restricted to, transcriptional terminators, extraneous sequences to enhance expression (such as introns [*e.g.* *Adh* intron 1], viral sequences [*e. g.* TMV- Ω]).

Constitutive Expression: the CaMV 35S Promoter

Construction of the plasmid pCGN1761 is described in the published patent application EP 0 392 225. pCGN1761 contains the "double" 35S promoter and the *tm1* transcriptional terminator with a unique *EcoRI* site between the promoter and the terminator and has a pUC-type backbone. A derivative of pCGN1761 is constructed which has a modified polylinker which includes *NotI* and *XhoI* sites in addition to the existing *EcoRI* site. This derivative is designated pCGN1761ENX. pCGN1761ENX is useful for the cloning of cDNA sequences or gene sequences (including microbial ORF sequences) within its polylinker for the purposes of their expression under the control of the 35S promoter in transgenic plants. The entire 35S promoter-gene sequence-*tm1* terminator cassette of such a construction can be excised by *HindIII*, *SphI*, *Sall*, and *XbaI* sites 5' to the promoter and *XbaI*, *BamHI* and *BglII* sites 3' to the terminator for transfer to transformation vectors. Furthermore, the double 35S promoter fragment can be removed by 5' excision with *HindIII*, *SphI*, *Sall*, *XbaI*, or *PstI*, and 3' excision with any of the polylinker restriction sites (*EcoRI*, *NotI* or *XhoI*) for replacement with another promoter.

Accordingly, a DNA molecule of the present invention is inserted into pCGN1761ENX for constitutive expression under the control of the CaMV 35S promoter.

Expression under a Chemically Regulatable Promoter

This section describes the replacement of the double 35S promoter in pCGN1761ENX with any promoter of choice; by way of example the chemically regulated PR-1a promoter is described. The promoter of choice is preferably excised from its source by restriction enzymes, but can alternatively be PCR-amplified using primers which carry appropriate terminal restriction sites. Should PCR-amplification be undertaken, then the promoter should be resequenced to check for amplification errors after the cloning of the amplified promoter in the target vector. The chemically regulatable tobacco PR-1a promoter is

cleaved from plasmid pCIB1004 (see EP 0 332 104) and transferred to plasmid pCGN1761ENX. pCIB1004 is cleaved with *NcoI* and the resultant 3' overhang of the linearized fragment is rendered blunt by treatment with T4 DNA polymerase. The fragment is then cleaved with *HindIII* and the resultant PR-1a promoter containing fragment is gel purified and cloned into pCGN1761ENX from which the double 35S promoter has been removed. This is done by cleavage with *XhoI* and blunting with T4 polymerase, followed by cleavage with *HindIII* and isolation of the larger vector-terminator containing fragment into which the pCIB1004 promoter fragment is cloned. This generates a pCGN1761ENX derivative with the PR-1a promoter and the *tml* terminator and an intervening polylinker with unique *EcoRI* and *NotI* sites.

A DNA molecule of the present invention is inserted into this vector, and the fusion product (*i.e.* promoter-gene-terminator) is subsequently transferred to any selected transformation vector, including those described in this application, thus providing for chemically inducible expression of the DNA molecule.

Constitutive Expression: the Actin Promoter

Several isoforms of actin are known to be expressed in most cell types and consequently the actin promoter is a good choice for a constitutive promoter. In particular, the promoter from the rice *Act1* gene has been cloned and characterized (McElroy *et al.* Plant Cell 2: 163-171 (1990)). A 1.3 kb fragment of the promoter is found to contain all the regulatory elements required for expression in rice protoplasts. Furthermore, numerous expression vectors based on the *Act1* promoter have been constructed specifically for use in monocotyledons (McElroy *et al.* Mol. Gen. Genet. 231: 150-160 (1991)). These incorporate the *Act1*-intron 1, *Adh1* 5' flanking sequence and *Adh1*-intron 1 (from the maize alcohol dehydrogenase gene) and sequence from the CaMV 35S promoter. Vectors showing highest expression are fusions of 35S and the *Act1* intron or the *Act1* 5' flanking sequence and the *Act1* intron. The promoter expression cassettes described by McElroy *et al.* (Mol. Gen. Genet. 231: 150-160 (1991)) is easily modified for the expression of a DNA molecule of the present invention and are particularly suitable for use in monocotyledonous hosts. For example, promoter containing fragments are removed from the McElroy constructions and used to replace the double 35S promoter in pCGN1761ENX, which is then available for the insertion of specific gene sequences. The fusion genes thus constructed are transferred to appropriate transformation vectors. In a separate report the rice *Act1*

promoter with its first intron has also been found to direct high expression in cultured barley cells (Chibbar *et al.* Plant Cell Rep. 12: 506-509 (1993)).

A DNA molecule of the present invention is inserted downstream of such promoter, and the fusion products (*i.e.* promoter-gene-terminator) are subsequently transferred to any selected transformation vector, including those described in this application.

Constitutive Expression: the Ubiquitin Promoter

Ubiquitin is another gene product known to accumulate in many cell types and its promoter has been cloned from several species for use in transgenic plants (*e.g.* sunflower - Binet *et al.* Plant Science 79: 87-94 (1991), maize - Christensen *et al.* Plant Molec. Biol. 12: 619-632 (1989)). The maize ubiquitin promoter has been developed in transgenic monocot systems and its sequence and vectors constructed for monocot transformation are disclosed in the patent publication EP 0 342 926. Further, Taylor *et al.* (Plant Cell Rep. 12: 491-495 (1993)) describe a vector (pAHC25) which comprises the maize ubiquitin promoter and first intron and its high activity in cell suspensions of numerous monocotyledons when introduced via microprojectile bombardment. The ubiquitin promoter is clearly suitable for the expression of a DNA molecule of the present invention in transgenic plants, especially monocotyledons. Suitable vectors are derivatives of pAHC25 or any of the transformation vectors described in this application, modified by the introduction of the appropriate ubiquitin promoter and/or intron sequences.

A DNA molecule of the present invention is therefore inserted into any of these vector, and the fusion products (*i.e.* promoter-gene-terminator) are used for transformation of plants, resulting in constitutive expression of the DNA molecule.

Root Specific Expression

A preferred pattern of expression for a DNA molecule of the instant invention is root expression. Expression of the nucleotide sequence only in root tissue has the advantage of altering the expression of a target gene only in roots, without a concomitant alteration of its expression in leaf and flower tissue and seeds. A suitable root promoter is that described by de Framond (FEBS 290: 103-106 (1991)) and also in the published patent application EP 0 452 269. This promoter is transferred to a suitable vector such as pCGN1761ENX and the DNA molecule is inserted into such vector. The entire promoter-gene-terminator cassette is subsequently transferred to a transformation vector of interest.

Wound Inducible Promoters

Numerous such promoters have been described (*e.g.* Xu *et al.* Plant Molec. Biol. 22: 573-588 (1993), Logemann *et al.* Plant Cell 1: 151-158 (1989), Rohrmeier & Lehle, Plant Molec. Biol. 22: 783-792 (1993), Firek *et al.* Plant Molec. Biol. 22: 129-142 (1993), Warner *et al.* Plant J. 3: 191-201 (1993)) and all are suitable for use with the instant invention. Logemann *et al.* (*supra*) describe the 5' upstream sequences of the dicotyledonous potato *wun1* gene. Xu *et al.* (*supra*) show that a wound inducible promoter from the dicotyledon potato (*pin2*) is active in the monocotyledon rice. Further, Rohrmeier & Lehle (*supra*) describe the cloning of the maize *Wip1* cDNA which is wound induced and which can be used to isolated the cognate promoter using standard techniques. Similarly, Firek *et al.* (*supra*) and Warner *et al.* (*supra*) have described a wound induced gene from the monocotyledon *Asparagus officinalis* which is expressed at local wound and pathogen invasion sites. Using cloning techniques well known in the art, these promoters can be transferred to suitable vectors, fused to a DNA molecule of this invention, and used to express these genes at the sites of insect pest infection.

Pith Preferred Expression

Patent application WO 93/07278 describes the isolation of the maize *trpA* gene which is preferentially expressed in pith cells. Using standard molecular biological techniques, this promoter or parts thereof, can be transferred to a vector such as pCGN1761 where it can replace the 35S promoter and be used to drive the expression of a DNA molecule of the present invention in a pith-preferred manner. In fact, fragments containing the pith-preferred promoter or parts thereof are transferred to any vector and modified for utility in transgenic plants. Pith preferred expression of the DNA molecule is achieved by inserting the DNA molecule in such vector.

Pollen-Specific Expression

Patent Application WO 93/07278 further describes the isolation of the maize calcium-dependent protein kinase (CDPK) gene which is expressed in pollen cells. The gene sequence and promoter extend up to 1400 bp from the start of transcription. Using standard molecular biological techniques, this promoter or parts thereof, is transferred to a vector such as pCGN1761 where it replaces the 35S promoter and is used to drive the expression of a DNA molecule of the present invention in a pollen-specific manner. In fact

fragments containing the pollen-specific promoter or parts thereof can be transferred to any vector and modified for utility in transgenic plants.

Leaf-Specific Expression

A maize gene encoding phosphoenol carboxylase (PEPC) has been described by Hudspeth & Grula (Plant Molec Biol 12: 579-589 (1989)). Using standard molecular biological techniques the promoter for this gene is used to drive the expression of a DNA molecule of the present invention in a leaf-specific manner in transgenic plants.

Example 6: Construction of Plant Transformation Vectors

Numerous transformation vectors are available for plant transformation, and a DNA molecule of this invention is inserted into any of the expression cassettes described above, such that they are capable of expressing the DNA molecule in desirable cells, under appropriate conditions. A nucleotide sequence-containing expression cassette is then incorporated into any appropriate transformation vector described below.

The selection of vector for use will depend upon the preferred transformation technique and the target species for transformation. For certain target species, different antibiotic or herbicide selection markers may be preferred. Selection markers used routinely in transformation include the *np^{III}* gene which confers resistance to kanamycin and related antibiotics (Messing & Vierra, Gene 19: 259-268 (1982); Bevan *et al.*, Nature 304:184-187 (1983)), the *bar* gene which confers resistance to the herbicide phosphinothricin (White *et al.*, Nucl Acids Res 18: 1062 (1990), Spencer *et al.* Theor Appl Genet 79: 625-631 (1990)), the *hph* gene which confers resistance to the antibiotic hygromycin (Blochinger & Diggelmann, Mol Cell Biol 4: 2929-2931), and the *dhfr* gene, which confers resistance to methatrexate (Bourouis *et al.*, EMBO J. 2(7): 1099-1104 (1983)).

Vectors Suitable for *Agrobacterium* Transformation

Many vectors are available for transformation using *Agrobacterium tumefaciens*. These typically carry at least one T-DNA border sequence and include vectors such as pBIN19 (Bevan, Nucl. Acids Res. (1984)) and pVictor HINK (SEQ ID NO: 5). Below the construction of two typical vectors is described.

Construction of pCIB200 and pCIB2001

The binary vectors pCIB200 and pCIB2001 are used for the construction of recombinant vectors for use with *Agrobacterium* and is constructed in the following manner. pTJS75kan is created by *NarI* digestion of pTJS75 (Schmidhauser & Helinski, J Bacteriol. 164: 446-455 (1985)) allowing excision of the tetracycline-resistance gene, followed by insertion of an *AccI* fragment from pUC4K carrying an NPTII (Messing & Vierra, Gene 19: 259-268 (1982); Bevan *et al.*, Nature 304: 184-187 (1983); McBride *et al.*, Plant Molecular Biology 14: 266-276 (1990)). *XhoI* linkers are ligated to the *EcoRV* fragment of pCIB7 which contains the left and right T-DNA borders, a plant selectable *nos/nptII* chimeric gene and the pUC polylinker (Rothstein *et al.*, Gene 53: 153-161 (1987)), and the *XhoI*-digested fragment is cloned into *Sall*-digested pTJS75kan to create pCIB200 (see also EP 0 332 104). pCIB200 contains the following unique polylinker restriction sites: *EcoRI*, *SstI*, *KpnI*, *BglII*, *XbaI*, and *Sall*. pCIB2001 is a derivative of pCIB200 which created by the insertion into the polylinker of additional restriction sites. Unique restriction sites in the polylinker of pCIB2001 are *EcoRI*, *SstI*, *KpnI*, *BglII*, *XbaI*, *Sall*, *MluI*, *BclI*, *AvrII*, *Apal*, *HpaI*, and *StuI*. pCIB2001, in addition to containing these unique restriction sites also has plant and bacterial kanamycin selection, left and right T-DNA borders for *Agrobacterium*-mediated transformation, the RK2-derived *trfA* function for mobilization between *E. coli* and other hosts, and the *OriT* and *OriV* functions also from RK2. The pCIB2001 polylinker is suitable for the cloning of plant expression cassettes containing their own regulatory signals.

Any one of the plant expression cassettes described above and comprising a DNA molecule of the present invention are inserted into pCIB2001, preferably using the polylinker.

Construction of pCIB10 and Hygromycin Selection Derivatives thereof

The binary vector pCIB10 contains a gene encoding kanamycin resistance for selection in plants, T-DNA right and left border sequences and incorporates sequences from the wide host-range plasmid pRK252 allowing it to replicate in both *E. coli* and *Agrobacterium*. Its construction is described by Rothstein *et al.* (Gene 53: 153-161 (1987)). Various derivatives of pCIB10 have been constructed which incorporate the gene for hygromycin B phosphotransferase described by Gritz *et al.* (Gene 25: 179-188 (1983)). These derivatives enable selection of transgenic plant cells on hygromycin only (pCIB743), or hygromycin and kanamycin (pCIB715, pCIB717). This vectors is used transform an expression cassette comprising a DNA molecule of the present invention.

V ctors Suitable for non-*Agrobacterium* Transformation

Transformation without the use of *Agrobacterium tumefaciens* circumvents the requirement for T-DNA sequences in the chosen transformation vector and consequently vectors lacking these sequences can be utilized in addition to vectors such as the ones described above which contain T-DNA sequences. Transformation techniques which do not rely on *Agrobacterium* include transformation via particle bombardment, protoplast uptake (e.g. PEG and electroporation), microinjection or pollen transformation (US Patent 5,629,183). The choice of vector depends largely on the preferred selection for the species being transformed. Below, the construction of some typical vectors is described.

Construction of pCIB3064

pCIB3064 is a pUC-derived vector suitable for direct gene transfer techniques in combination with selection by the herbicide basta (or phosphinothricin). The plasmid pCIB246 comprises the CaMV 35S promoter in operational fusion to the *E. coli* GUS gene and the CaMV 35S transcriptional terminator and is described in the PCT published application WO 93/07278. The 35S promoter of this vector contains two ATG sequences 5' of the start site. These sites are mutated using standard PCR techniques in such a way as to remove the ATGs and generate the restriction sites *SspI* and *PvuII*. The new restriction sites are 96 and 37 bp away from the unique *SalI* site and 101 and 42 bp away from the actual start site. The resultant derivative of pCIB246 is designated pCIB3025. The GUS gene is then excised from pCIB3025 by digestion with *SalI* and *SacI*, the termini rendered blunt and religated to generate plasmid pCIB3060. The plasmid pJIT82 is obtained from the John Innes Centre, Norwich and the a 400 bp *SmaI* fragment containing the *bar* gene from *Streptomyces viridochromogenes* is excised and inserted into the *HpaI* site of pCIB3060 (Thompson *et al.* EMBO J 6: 2519-2523 (1987)). This generated pCIB3064 which comprises the *bar* gene under the control of the CaMV 35S promoter and terminator for herbicide selection, a gene for ampicillin resistance (for selection in *E. coli*) and a polylinker with the unique sites *SphI*, *PstI*, *HindIII*, and *BamHI*. This vector is suitable for the cloning of plant expression cassettes containing their own regulatory signals to direct expression of a DNA molecule of the present invention.

Construction of pSOG19 and pSOG35

pSOG35 is a transformation vector which utilizes the *E. coli* gene dihydrofolate reductase (DHFR) as a selectable marker conferring resistance to methotrexate. PCR is used to amplify the 35S promoter (~800 bp), intron 6 from the maize Adh1 gene (~550 bp) and 18 bp of the GUS untranslated leader sequence from pSOG10. A 250 bp fragment encoding the *E. coli* dihydrofolate reductase type II gene is also amplified by PCR and these two PCR fragments are assembled with a *SacI-PstI* fragment from pBI221 (Clontech) which comprised the pUC19 vector backbone and the nopaline synthase terminator. Assembly of these fragments generated pSOG19 which contains the 35S promoter in fusion with the intron 6 sequence, the GUS leader, the DHFR gene and the nopaline synthase terminator. Replacement of the GUS leader in pSOG19 with the leader sequence from Maize Chlorotic Mottle Virus (MCMV) generated the vector pSOG35. pSOG19 and pSOG35 carry the pUC gene for ampicillin resistance and have *HindIII*, *SphI*, *PstI* and *EcoRI* sites available for the cloning of foreign sequences, in particular a DNA molecule of the present invention.

Example 7: Chloroplast Transformation

Transformation vectors

For expression of a DNA molecule of the present invention in plant plastids, plastid transformation vector pPH143 (WO 97/32011, example 36) is used. The DNA molecule is inserted into pPH143 thereby replacing the PROTOX coding sequence. This vector is then used for plastid transformation and selection of transformants for spectinomycin resistance. Alternatively, the DNA molecule is inserted in pPH143 so that it replaces the *aadH* gene. In this case, transformants are selected for resistance to PROTOX inhibitors.

Chloroplast Transformation

Seeds of *Nicotiana tabacum* c.v. 'Xanthi nc' were germinated seven per plate in a 1" circular array on T agar medium and bombarded 12-14 days after sowing with 1 μ m tungsten particles (M10, Biorad, Hercules, CA) coated with DNA from plasmids pPH143 and pPH145 essentially as described (Svab, Z. and Maliga, P. (1993) *PNAS* 90, 913-917). Bombarded seedlings were incubated on T medium for two days after which leaves were excised and placed abaxial side up in bright light (350-500 μ mol photons/m²/s) on plates of RMOP medium (Svab, Z., Hajdukiewicz, P. and Maliga, P. (1990) *PNAS* 87, 8526-8530) containing 500 μ g/ml spectinomycin dihydrochloride (Sigma, St. Louis, MO). Resistant shoots

appearing underneath the bleached leaves three to eight weeks after bombardment were subcloned onto the same selective medium, allowed to form callus, and secondary shoots isolated and subcloned. Complete segregation of transformed plastid genome copies (homoplasmy) in independent subclones was assessed by standard techniques of Southern blotting (Sambrook et al., (1989) Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring Harbor). BamHI/EcoRI-digested total cellular DNA (Mettler, I. J. (1987) *Plant Mol Biol Reporter* 5, 346–349) was separated on 1% Tris-borate (TBE) agarose gels, transferred to nylon membranes (Amersham) and probed with ³²P-labeled random primed DNA sequences corresponding to a 0.7 kb BamHI/HindIII DNA fragment from pC8 containing a portion of the *rps7/12* plastid targeting sequence. Homoplasmic shoots are rooted aseptically on spectinomycin-containing MS/IBA medium (McBride, K. E. et al. (1994) *PNAS* 91, 7301-7305) and transferred to the greenhouse.

Example 8: Construction of a chimeric gene cassette encoding a sense and antisense (duplex) RNA fragment for the coat protein gene from BWYV, driven by the *Ro/C* promoter

An 0.6 Kb 'sense' oriented fragment of the beet western yellows virus (BWYV), a so-called virus yellow, coat protein (CP) gene is amplified from plasmid pZU046 using primers HiNK025bis (5' -CAA TTA CCA TGG ACA CGG TCG TGG-3', SEQ ID NO: 6; *NcoI* restriction site underlined), and HiNK226 (5' -GCC AAA TGT TTG AAC GCT GCA GCC TAT TTG-3', SEQ ID NO: 7; *PstI* restriction site underlined). Alternatively the fragment is amplified from plasmid pBW17 (Veidt et al, *Nucleic Acids Research* 16: 9917-9932, 1988; accession number X13063) using primers HiNK025bis2 (5' -AAT CGT CCA TGG ATA CGG TCG TGG-3', SEQ ID NO: 8; nucleotides 3475 to 3498, *NcoI* restriction site underlined), and HiNK226bis (5' -CTA GGG CCG GGT TCC TCT GCA GCC TAT TTG-3', SEQ ID NO: 9; nucleotides 4114 to 4085, *PstI* restriction site underlined). *Taq* DNA Polymerase (Life Technologies) is used in 25µl reactions according to the manufacturer's prescription applying 30 cycles of 94°C/30 sec, 55°C/30 sec, 72°C/90 sec (+2 sec/cycle). The resulting PCR fragment is purified by electrophoresis through a 1% Tris-acetate gel made from Seakem GTG agarose (FMC), followed by an extraction of the gel slices containing the PCR product with QIAquick Gel Extraction Kit (QIAGEN). The PCR product is subsequently digested with *NcoI* and *PstI* (all restriction enzymes were supplied by Life Technologies) according to standard methods and again gel purified. The purified fragment

is ligated between the *Ro/C* promoter and the *Nos* terminator using T4 DNA ligase (Life Technologies). The resulting clone is named pHiNK138.

In a similar manner as described above a 1.4 Kb 'antisense' oriented BWYV CP fragment is amplified from plasmid pZU174A using primers HiNK251 (5' -CTC CCA GGT TGA GAC TGC CCT GCA GTG CCC A-3', SEQ ID NO: 10; *Pst*I restriction site underlined) and HiNK228 (5' -TTA CCA TGC ATA CGG TCG TGG GTA GG-3', SEQ ID NO: 11; *Nsi*I restriction site underlined) or from plasmid pBW17 using primers HiNK251 (nucleotides 4844 to 4814) and HiNK228bis (5' -CGT TAA TGC ATA CGG TCG TGG GTA GG-3', SEQ ID NO: 12; nucleotides 3478 to 3503, *Nsi*I restriction site underlined). Upon gel purification the PCR product is digested with *Nsi*I and *Pst*I. The 4.9 Kb plasmid pHiNK138 is linearised with *Pst*I and dephosphorylated using the Thermosensitive Alkaline Phosphatase (Life Technologies). Both the vector and the PCR fragment are gel purified, followed by the bidirectional ligation of the PCR fragment into pHiNK138. The orientation generating the duplex RNA for the CP gene (SEQ ID NO: 13) is identified by restriction site analysis, yielding plasmid pHiNK152 in which the inverted repeat consists of the 0.6 Kb CP gene separated by the 0.7 Kb spacer sequence derived from the BWYV genome downstream of the CP gene, referred to as ORF6. The spacer sequence is in the antisense orientation. Finally, the said gene cassette is transferred to the proprietary binary vector pVictorHiNK carrying phosphomannose isomerase as selectable marker gene (WO 94/20627), yielding pHiNK179.

Example 9.1: Construction of a chimeric gene cassette encoding a sense and antisense (duplex) RNA fragment for the replicase gene from BNYVV, driven by the *Arabidopsis Ubi3Int* promoter

Total RNA is extracted from sugar beet root infected by the beet necrotic yellow vein virus (BNYVV), a furovirus, using the RNAeasy Plant mini kit from QIAGEN. In order to amplify the 3' end of the BNYVV replicase gene (RNA1) the RNA is reverse transcribed to produce a cDNA using the SuperscriptTM II RNase H-Reverse Transcriptase (RT) (Life Technologies) and the reverse primer HiNK285 (5' -TCG TAG AAG AG A ATT CAC CCA AAC TAT CC-3', SEQ ID NO: 14). Primer HiNK285 is located between nucleotides 6378 and 6405 of the BNYVV RNA1 sequence (accession number D00115) and designed to introduce an *EcoRI* site. The RT reaction is subsequently used as template for two PCR reactions :

- Reaction A using primer HiNK283 (5' -AAG AAT TGC AGG ATC CAC AGG CTC GGT AC-3', SEQ ID NO: 15) located between nucleotides 5168 bp and 5178 bp of BNYVV RNA1 designed to introduce a *Bam*HI site, and primer HiNK284 (5' -TTC CAA CGA ATT CGG TCT CAG AC A-3', SEQ ID NO: 16) located between nucleotides 5597 and 5620 of BNYVV RNA1 designed to introduce an *Eco*RI site.
- Reaction B using primer HiNK283 in combination with primer HiNK285, both described above.

The thus obtained RT-PCR products share the BNYVV RNA1 sequence between nucleotides 5168-5620 that constitutes the future RNA duplex. The future spacer sequence corresponds to nucleotides 5621-6405 bp of BNYVV RNA1 present at the RT-PCR product obtained with primers HiNK283 and HiNK285.

Taq DNA Polymerase (Life Technologies) is used in 25µl reactions according to the suppliers's prescription applying 30 cycles of 94°C/30 sec, 55°C/30 sec, 72°C/90 sec(+2 sec/cycle). The resulting RT-PCR products are purified by electrophoresis through a 1% Tris-acetate gel made from Seakem GTG agarose (FMC), followed by an extraction of the gel slices containing the amplification products with the QIAquick Gel Extraction Kit (QIAGEN). After gel purification, the RT-PCR products are digested with restriction enzymes *Bam*HI and *Eco*RI (Life Technologies) according to standard methods and purified as described above.

Finally the RT-PCR products are cloned between the *Arabidopsis* Ubiquitin3 (*Ubi3int*) promoter and the *Nos* terminator by means of a three-way ligation reaction using T4 DNA ligase (Life Technologies). The two resulting clones are named pHiNK181 (spacer in antisense orientation, see SEQ ID NO: 17) and pHiNK184 (spacer in sense orientation, see SEQ ID NO: 18).

In order to construct the binary vectors for the *Agrobacterium*-mediated transformation of sugar beet, DNA from binary vector pVictorHiNK carrying the phosphomannose isomerase gene as selectable marker (WO 94/20627), as well as plasmids pHiNK181 and pHiNK184, are digested with *Asc*I and *Pac*I (New England Biolabs) and the vector and insert fragments purified by electrophoresis as described above. The resulting 7.7 kb pVictorHiNK vector fragment is ligated using T4 DNA ligase (Life Technologies) to the gene cassettes encoding the duplex RNA for the BNYVV replicase gene yielding pHiNK187 (antisense spacer) and pHiNK188 (sense spacer) respectively.

Example 9.2: *Agrobacterium*-mediated transformation of sugar beet

Methods for the *Agrobacterium*-mediated transformation of plants species are well established and known to a person skilled in the art, and may vary for the explant type, the *Agrobacterium* strain, or the selectable marker and regeneration system used. The protocol here below describes the *Agrobacterium*-mediated transformation of sugar beet using cotyledons as source for explants and mannose-6-phosphate isomerase as selectable marker gene (Joersbo et al, Molecular Breeding 4: 111-117, 1998). Upon surface sterilization sugar beet seeds are germinated on water agar and under dim light at a temperature of approximately 12°C. Fully developed cotyledons are removed from the seedling by a transversal cut just below the nodal region and both cotyledons torn apart by gentle pulling and cutting. Cotyledon explants are inoculated by dipping them into a suspension of *Agrobacterium* strain EHA101 carrying the appropriate transformation vector diluted in MS medium pH 5.2, supplemented with 20 g/l sucrose, 0.25 mg/l BA, 0.05 mg/l NAA, 500 µM acetosyringone diluted to an optical density (OD₆₀₀) from 0.1 to 0.3. After five minutes of incubation explants are removed from the *Agrobacterium* suspension, dipped on sterile filter paper to remove excess of the inoculation suspension, and transferred to co-cultivation plates. The co-cultivation plates consist of petri dishes containing 1/10 MS medium pH 5.7, 30 g/l sucrose, 200 µM acetosyringone, solidified with 4.7 g/l agarose and covered with a filter paper moistened with 1.5 ml TXD medium (MS salts supplemented with PGO vitamins, 0.005 mg/l kinetin, 4 mg/l CPA (*p*-chlorophenoxy acetic acid), 30 g/l sucrose, pH 5.7) on the top of the solidified medium. Explants are co-cultivated during 4 days at 21°C and under dim light, and subsequently transferred to selective regeneration medium consisting of MS medium pH 5.9 supplemented with 20 g/l sucrose, 1.25 g/l mannose, 0.25 mg/l BA, 0.05 mg/l NAA, 500 mg/l carbenicillin, and solidified with 9 g/l agar. Every third week the explants are subcultured to fresh media containing gradually increasing concentrations of mannose to a maximum of 15 g/l. After 12 weeks of selection and regeneration at a temperature of 21°C, regenerated shoots are harvested, rooted and analyzed for PMI activity essentially according to the coupled enzyme assay described by Feramisco and co-workers (Feramisco et al, Biochem. Biophys. Res. Comm. 55: 636-641, 1973). Positive plants are potted in soil and finally transferred to the greenhouse.

Example 9.3: Screening for resistance to rhizomania

Upon sowing or potting to soil, seedlings or T0 transformants are first allowed to establish a sufficiently developed root system for a period of approximately four weeks, prior to their transfer to soil infested with *Polymyxa betae* carrying BNYVV. Infested soils are collected from rhizomania infected fields in Germany. During the resistance assay plants are grown in 12 cm pots at a temperature of approximately 21°C and light period of 16 hours. Four weeks after transplantation into the infested soil, plants are pulled from the soil and the bottom half of the root system cleaned from any adhering dirt by rinsing with water. Sap from a random sample of 0.5 g of root tissue is collected by means of a Pollähne press and added to 10 ml of extraction buffer consisting of phosphate buffered saline pH 7.2, supplemented with 2% PVP and 0.2% ovalbumin. The amount of virus present in the samples (clones are obtained by *in vitro* propagation) is determined by means of the triple antibody sandwich (TAS) ELISA for BNYVV commercialized by Adgen Ltd, Scotland, UK, essentially following the supplier's instruction. A standard curve is included on each plate to calculate the virus content of the root samples from the measured absorbance values. Non-transformed susceptible sugar beet plants serve as negative controls, plants carrying the C28 gene for natural rhizomania resistance as positive controls. Table 1 summarizes the results of transformation events obtained with plasmid pHINK188.

Table 1:

Event	Clone number	ELISA value	Virus content ng/ml
Event 279-15-A	1	3.265	>900
	2	3.420	>900
	3	2.987	>900
Event 284-22-A	1	0.119	4
Event 284-22-G	1	0.022	0
	2	0.006	0
Event 284-22-I	1	0.010	0
Event 284-22-M	1	1.400	216
	2	1.127	138
Event 284-22-Q	1	0.447	29
	2	0.049	1
Event 284-22-U	1	3.420	>900
	2	3.582	>900

Event	Clin number	ELISA value	Virus content ng/ml
Event 284-22-1F	1	3.945	>900
	2	0.131	4
C28 positive control	1	0.677	56
	2	0.679	56
	3	0.377	22
	4	0.756	67
	5	1.122	137
	6	0.640	51
Negative control A	1	3.186	>900
	2	3.362	>900
	3	3.487	>900
	4	3.311	>900
	5	3.478	>900
Negative control B	1	3.678	>900
	2	3.582	>900
	3	3.326	>900
	4	3.502	>900
	5	3.330	>900
	6	3.439	>900
	7	3.439	>900
	8	3.682	>900

Example 10: Construction of a plant transformation vector for Zucchini yellow mosaic potyvirus (ZYMV) and Papaya ringspot potyvirus (PRSV) resistance in Melon:

The NOS terminator (Bevan, M., et al, 1983 *Nucleic Acids Res.* 11 (2), 369-385) is cloned as 260 bp HindIII/PstI fragment into the plasmid pZO1560 digested with HindIII/PstI.

PZO1560 is a pUC derived plasmid in which the multiple cloning site has been replaced by a more versatile one. The new construct obtained after insertion of the NOS terminator is named pZU533.

The 1728 bp Ubi3 promoter/intron fragment (Callis, J., et al, (1995 *Genetics* 139 (2), 921-939) is isolated by digestion with BamHI followed by a T4 DNA polymerase treatment and KpnI digestion. This fragment is cloned into pZU533 digested with SmaI. The new construct is named pZU615.

Additional DNA fragments to be inserted into pZU615 are firstly amplified by PCR using Pfx DNA polymerase and the PCR fragments obtained are cloned into pBluescript SK+.

To amplify a 513 bp Actin2 IntronL (leader intron) fragment two primers are designed based on the sequence from An et al, *The Plant Journal*: 10: 107-121, 1996. The 5' primer (ZUP1563: 5' -GGGCGGATCCGCTAGCCCGCGGCCGCTCTTTCTTTCCAAGG-3', SEQ ID NO: 19) anneals directly upstream of the 5' splice site and adds a BamHI, a NheI and a SacII restriction site to the 5'-end of the Actin2 IntronL fragment to be amplified. The 3' primer (ZUP1564: 5' -CCCGCCATGGGTCGACGCCATTTTTTATGAGCTGC-3', SEQ ID NO: 20) anneals directly downstream of the 3' splice site and adds a SalI and a NcoI restriction site to the 3'-end of the Actin2 IntronL fragment to be amplified. The PCR fragment amplified with ZUP1563 and 1564 is cloned in the EcoRV site of pBluescript. The new plasmid is named pZU611. To provide plasmid pZU615 with the Act2 IntronL a 499 bp BamH/NcoI Act2 IntronL fragment is isolated from pZU611 and cloned in pZU615 digested with BamHI and NcoI downstream of the Ubi3 promoter/intron and upstream of the NOS terminator. The new construct is designated pZU616. The insertion of this fragment simultaneously provides the cassette with five additional restriction sites for the next three cloning steps.

To amplify a non-translated (nt) 739 bp PRSV CP fragment (Shyi-Dong, Y., et al, (1992).

Journal of General Virology 73, 2531-2541) two primers are designed based on the sequence of a French field isolate from Shyi-Dong Yeh. The 5' primer (ZUP1565: 5' -CCCGCCATGGGATCCGATGATTTCTACCGAGAATTAAGGG -3', SEQ ID NO: 21) anneals 285 bp downstream of the start codon of PRSV CP and adds a NcoI and a BamHI restriction site to the 5'-end of the non-translated PRSV CP fragment. The 3' primer (ZUP1566: 5' -GGGCGCTAGCCTAATGCTTATATAGTACC-3', SEQ ID NO: 22) anneals 55 bp downstream of the PRSV CP stop codon and adds a NheI restriction site to the 3'-end of the non-translated PRSV CP fragment. The amplified PCR fragment is cloned in the EcoRV site of pBluescript and the new plasmid is designated pZU612.

To amplify a 735 bp non-translated ZYMV CP fragment (Gal-On, A., et al, (1990). *Gene* 87, 273-277) two primers are designed based on the sequence of a French field isolate from Gal-On, A.. The 5' primer (ZUP1567: 5' - GGGCGCTAGCCTTGCTGGAGTATAAGCCGG -3', SEQ ID NO: 23) anneals 253 bp downstream of the start codon of ZYMV CP and includes a NheI restriction site at the 5'-end of the ZYMV CP non-translated fragment. The 3' primer (ZUP1568: 5' - GGGCGTCGACCGCGGGCTTTAAAGGTGGGAGGCC -3', SEQ ID NO: 24) anneals 89 bp downstream of the ZYMV CP stop codon and includes SacII and a SalI

restriction sites at the 3' end of the non-translated ZYMV CP fragment. The amplified PCR fragment is cloned in the EcoRV site of pBluescript. The new plasmid is named pZU613. A ZYMV CP non-translated fragment is subsequently cloned into pZU616 downstream of the Ubi3 promoter/intron and upstream of the Act2 IntronL. For this purpose a 719 bp NheI/SacII ZYMV CP non-translated fragment is isolated from pZU613 and cloned in the NheI and SacII sites of pZU616. The construct is designated pZU617. Subsequently a PRSV CP non-translated fragment is cloned into pZU617 downstream of the Ubi3 promoter/intron and upstream of the ZYMV CP non-translated fragment. For this purpose a 720 bp BamHI/NheI PRSV CP non-translated fragment is isolated from pZU612 and cloned in the BamHI and NheI sites of pZU617. This new construct is named pZU618.

The last fragment to be cloned to complete the gene cassette contains a PRSV CP non-translated fragment and downstream thereof a ZYMV CP non-translated fragment in the same orientation. A corresponding fragment is amplified from pZU618 as template using Pfx PCR and the primers ZUP1565 and ZUP1568. The PCR fragment is cloned into the EcoRV site of pBluescript SK+ and the resulting plasmid is named pZU619.

To create an inverted repeat gene cassette the PRSV CP (nt) / ZYMV CP (nt) fragment is inserted in pZU618 in opposite direction of the PRSV CP (nt) / ZYMV CP (nt) fragments already present in the pZU618 plasmid. For this purpose a 1445 bp SalI/NcoI PRSV CP (nt) / ZYMV CP (nt) fragment is isolated from pZU619 and cloned in pZU618 digested with SalI and NcoI downstream of the Act2 IntronL and upstream of the NOS terminator. The resulting plasmid is designated pZU622. Said cassette is inserted into the binary vector pZU547, a binary vector derived from the plasmid pVictorHink additionally containing a SMAS promoter / PMI / NOS terminator selection cassette. To this end the 5414 bp Ascl/PacI DNA fragment containing the inverted repeat gene cassette is isolated from pZU622 and cloned into the Ascl and PacI sites of pZU547 in tandem orientation and upstream of the selection cassette. The final construct is designated pZU623 (SEQ ID NO: 25).

Example 11: Construction of a plant transformation vector for Potato Virus Y (PVY) resistance in Tomato

Based on the sequence of PVYn (a French field isolate of PVY), published in the thesis 'Engineering resistance against potato virus Y' of R.A.A. van der Vlugt (1993), two primers (ZUP1598: 5' -CATGCCATGGATCCAATGGCCACGAATTAAAGCTATCACGTC-3' - SEQ ID NO: 26, and ZUP1590: 5' -ACGCGTCGACCGCGGATTCAAACGATTATTAATTACGATAAAAG-3' -

SEQ ID NO: 27) are used to amplify by standard PCR techniques using Platinum Pfx DNA polymerase from Life Technologies a 804 bp fragment containing the coat protein cistron sequences and 99 nucleotides of the 3'-end non-translated region. The amplified PCR fragment is cloned as a blunt end fragment in the EcoRV site of pBluescript SK+ the plasmid being designated pZUA. The amplified PVY specific insert is excised from as a BamHI/SacII fragment and cloned into the BamHI/SacII sites of pZU616 (see example 10), yielding pZUB. pZUB and pZUA are both digested with NcoI and Sall. The PVY specific fragment from pZUA is purified from agarose gel and ligated into the pZUB digested with NcoI and Sall, yielding pZUC containing the following elements:

The UBI3 promoter with intron followed by the PVY PCR product in sense orientation as a BamHI/SacII fragment, followed by a SacII/Sall ACT2 intron, followed by the PVY PCR product in antisense orientation as a Sall/NcoI fragment and finally a nos terminator as a NcoI/HindIII fragment. Finally, pZUC is cloned into the binary vector pZU547 containing the SMAS promoter / PMI / NOS terminator selection cassette derived from the pHiNK 085 binary vector. The final construct is designated pZU634 (SEQ ID NO: 28).

Example 12: Transformation of binary vectors to melon and tomato plant material

Methods to transfer binary vectors to plant material are well established and known to a person skilled in the art. Variations in the procedures are due to, for instance, differences in *Agrobacterium* strains used, different sources of explant material, differences between the regeneration systems, as well as different cultivars of the plant species to be transformed. The binary plant transformation vectors described in examples 10 and 11 above are used in transformation experiments according to the following procedures. The binary vectors are transferred to *Agrobacterium tumefaciens* by electroporation, followed by inoculation and cocultivation of plant explant material with the transformed *Agrobacterium* strain, selective killing of the *Agrobacterium* strain using an appropriate antibiotic, selection of transformed cells by growing on selective media containing mannose, transfer of tissue to shoot inducing media, transfer of selected shoots to root inducing media, and transfer of plantlets to soil. To confirm the presence of the gene cassettes described in examples 10 and 11 above, total DNA from the transgenic plants is characterized using well known Southern Blot Analysis techniques.

Example 13: Screening transgenic melon plants for ZYMV and PRSV resistance

Transformed plants are grown in the greenhouse under standard quarantine conditions in order to prevent any infections by pathogens. Primary transformants are self pollinated and seeds harvested.

100 plants of the S1 progeny of the primary transformants are analyzed for segregation of the inserted gene and subsequently infected with ZYMV by mechanical inoculation. Tissue from host plants systemically infected with ZYMV is ground in 5 volumes of ice cold inoculation buffer (10mM phosphate buffer) and rubbed in the presence of carborundum powder on the cotyledons and first leaves of 1 week old seedlings. Inoculated plants are monitored for symptom development during 3 weeks after inoculation. Plants containing ZYMV sequences show reduced susceptibility to ZYMV infection compared with untransformed control plants which show severe systemic ZYMV symptoms within 7 days after inoculation. ZYMV tolerant plants are self pollinated and seeds harvested. Transgenic ZYMV resistant plants are mechanically inoculated with PRSV according to the procedures described above. Plants already resistant to ZYMV also show reduced susceptibility to PRSV infection compared with untransformed control plants which show severe systemic PRSV symptoms within 7 days after inoculation.

Example 14: Screening of transgenic tomato plants for resistance against PVY

Transformed plants are grown in the greenhouse under standard quarantine conditions in order to prevent any infections by pathogens. Primary transformants are self pollinated and seeds harvested.

50 plants of the S1 progeny of the primary transformants are analyzed for segregation of the inserted gene and subsequently infected with PVY by mechanical inoculation. Tissue from host plants systemically infected with PVY is ground in 5 volumes of ice cold inoculation buffer (10mM phosphate buffer) and rubbed in the presence of carborundum powder on the first two fully extended leaves of 5 weeks old seedlings. Inoculated plants are monitored for symptom development during 3 weeks after inoculation. Plants containing PVY sequences show reduced susceptibility to PVY infection compared with untransformed control plants which show severe systemic PVY symptoms within 7 days after inoculation.

The above disclosed embodiments are illustrative. This disclosure of the invention will place one skilled in the art in possession of many variations of the invention. All such obvious and foreseeable variations are intended to be encompassed by the appended claims.

What is claimed is:

1. A method of altering the expression of a viral genome comprising introducing into a cell a first DNA sequence capable of expressing in said cell a sense RNA fragment of said viral genome and a second DNA sequence capable of expressing in said cell an antisense RNA fragment of said viral genome, wherein said sense RNA fragment and said antisense RNA fragment are capable of forming double-stranded RNA.
2. The method of claim 1 rendering said cell virus resistant or tolerant.
3. The method of claim 1, wherein said cell is a plant cell.
4. The method of claim 1, wherein said virus is selected from the group consisting of tospoviruses, potyviruses, potexviruses, tobamoviruses, luteoviruses, cucumoviruses, bromoviruses, closteorviruses, tombusviruses and furoviruses.
5. The method of claim 1, wherein said DNA sequences comprises a nucleotide sequence derived from a viral coat protein gene, a viral nucleocapsid protein gene, a viral replicase gene, or a viral movement protein gene.
6. The method of claim 1, wherein said first DNA sequence and said second DNA sequence are stably integrated in the genome of said cell.
7. The method of claim 1, wherein said first DNA sequence and said second DNA sequence are comprised in two separate DNA molecules.
8. The method of claim 1, wherein at least two pairs of first and second DNA sequences are introduced into a cell.
9. The method of claim 8, wherein each pair of DNA sequences encodes sense and antisense RNA fragments of different virus species or isolates.
10. The method of claim 1, wherein said first DNA sequence and said second DNA sequence are comprised in one DNA molecule.
11. The method of claim 10, wherein said first DNA sequence and said second DNA sequence are comprised in the same DNA strand of said DNA molecule.
12. The method of claim 11, wherein said sense RNA fragment and said antisense RNA fragment are comprised in one RNA molecule.

13. The method of claim 12, wherein said RNA molecule is capable of folding such that said RNA fragments comprised therein form a double-stranded region.
14. The method of claim 1, wherein the the expressed RNA molecule comprises the inverted repeat sequence of SEQ ID NO: 13, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 25 or SEQ ID NO: 28.
15. The method of claim 24, wherein expression of said RNA molecule is driven by a heterologous, a tissue-specific, a developmentally regulated, a constitutive, or an inducible promoter.
16. The method of claim 15, wherein expression of said RNA molecule is driven by a ubiquitin promoter such as the Arabidopsis Ubi3 promoter.
17. The method of claim 15, wherein expression of said RNA molecule is driven by the Agrobacterium rolC promoter.
18. The method of claim 12, wherein said DNA molecule comprises a linker between the DNA sequences encoding said sense RNA fragment and said antisense RNA fragments.
19. The method of claim 18, wherein the linker is defined by the nucleotide sequence of the leader intron of the Arabidopsis Actin 2 gene.
20. The method of claim 18, wherein the linker is defined by a nucleotide sequence of the viral region flanking the sense or antisense RNA fragment.
21. The method of claim 18, wherein said linker comprises an expression cassette of a functional gene such as a selectable marker gene.
22. The method of claim 21, wherein said linker comprises regulatory sequences such as intron processing signals.
23. The method of claim 11, wherein said sense RNA fragment and said antisense RNA fragment are comprised in two separate RNA molecules.
24. The method of claim 23, wherein said first DNA sequence and said second DNA sequence are operably linked to a bi-directional promoter.
25. The method of claim 11, wherein said first DNA sequence and said second DNA sequence are comprised in complementary strands of said DNA molecule.

26. The method of claim 25, wherein said first DNA sequence is the complementary DNA strand of said second DNA sequence in said DNA molecule.
27. A DNA construct altering the expression of a viral genome comprising a first DNA sequence capable of expressing in a cell a sense RNA fragment of said viral genome and a second DNA sequence capable of expressing in said cell an antisense RNA fragment of said viral genome, wherein said sense RNA fragment and said antisense RNA fragment are capable of forming a double-stranded RNA molecule.
28. The DNA construct of claim 27, wherein said DNA construct comprises a first promoter operably linked to said first DNA sequence and a second promoter operably linked to said second DNA sequence.
29. The DNA construct of claim 27, wherein said DNA construct comprises a bi-directional promoter operably linked to said first DNA sequence and to said second DNA sequence.
30. A cell showing altered expression of a viral genome comprising a first DNA sequence capable of expressing in said cell a sense RNA fragment of said viral genome and a second DNA sequence capable of expressing in said cell an antisense RNA fragment of said viral genome, wherein said sense RNA fragment and said antisense RNA fragment are capable of forming double-stranded RNA.
31. A plant and the progeny thereof derived showing altered expression of a viral genome comprising a first DNA sequence capable of expressing in said cell a sense RNA fragment of said viral genome and a second DNA sequence capable of expressing in said cell an antisense RNA fragment of said viral genome, wherein said sense RNA fragment and said antisense RNA fragment are capable of forming double-stranded RNA.
32. The plant of claim 31, wherein said plant is virus resistant or tolerant.
33. Seeds derived from the plant of claim 31.

SEQUENCE LISTING

<110> Novartis AG

<120> Regulation of Viral Gene Expression

<130> S-30959A

<140>

<141>

<150> US 09/309038

<151> 1999-05-10

<160> 28

<170> PatentIn Ver. 2.1

<210> 1

<211> 27

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: ds_Luc1

<400> 1

cgcggtatcct ggaagacgcc aaaaaca

27

<210> 2

<211> 38

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: ds_Luc2

<400> 2

cggaagctta ggctcgccta atcgagtat ccggaatg

38

<210> 3

<211> 28

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: ds_Luc3

<400> 3

cgtctagag gaagacgcca aaaacata

28

<210> 4

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: JG-L

<400> 4

gtacctcgag tctagactcg ag

22

<210> 5

<211> 4732

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: pVictorHINK

<400> 5

```

gcacgaaccc cccgttcagc ccgaccgctg cgccttatcc ggtaactatc gtcttgagtc 60
caaccgggta agacacgact tatcgccact ggcagcagcc actggtaaca ggattagcag 120
agcgagggtat gtaggcggtg ctacagagtt cttgaagtgg tggcctaact acggctacac 180
tagaaggaca gtatcttggtg tctgcgctct gctgaagcca gttaccttcg gaaaaagagt 240
tggtagctct tgatccgga aacaaaccac cgctggtagc ggtggttttt ttgtttgcaa 300
gcagcagatt acgcgcagaa aaaaaggatc tcaagaagat cctttgatct tttctacggg 360
gtctgacgct cagtggaaag aaaactcacg ttaagggatt ttggtcatga gattatcaaa 420
aaggatcttc acctagatcc ttttgatccg gaattaattc ctgtggttg catgcacata 480
caaatggagc aacggataaa ccttttcacg cccttttaaa tatccgatta ttctaataaa 540
cgctcttttc tcttaggttt acccgccaat atatcctgtc aaacactgat agtttaaact 600
gaaggcggga aacgacaatc tgatcatgag cggagaatta agggagtcac gttatgacct 660
ccgccgatga cgcgggacaa gccgttttac gtttggaact gacagaaccg caacgctgca 720
ggaattggcc gcagcgcca tttaaatcaa ttgggcgcgc cgaattcgag ctcggtacct 780
ggggatcctc tagagtcgac catggtgatc actgcaggca tgcaagcttc gtacgttaat 840
taattcgaat ccggagcggc cgcacgcgtg ggcgcgttta aacctcgaga gatctgctag 900
ccctcgagga aatttaccgg tgcccgggcg gccagcatgg ccgtatccgc aatgtgttat 960
taagtgtct aagcgtcaat ttgtttacac cacaatatat cctgccacca gccagccaac 1020
agctccccga cggcagctc ggcacaaaat caccactcga tacaggcagc ccatcagaat 1080
taattctcat gtttgacagc ttatcatcga ctgcacggtg caccaatgct tctggcgtca 1140
ggcagccatc ggaagctgtg gtatggctgt gcaggctcgt aatcactgca taattcgtgt 1200
cgctcaaggc gcaactccgt tctggataat gttttttgcg ccgacatcat aacggttctg 1260
gcaaataatc tgaaatgagc tgttgacaat taatcatcgg ctctgataat gtgtggaatt 1320
gtgagcggat aacaatttca cacaggaaac agaccatgag ggaagcggtg atcgccgaag 1380
tatcgactca actatcagag gtagttggcg tcatcgagcg ccatctcgaa ccgacgttgc 1440
tgggcgtaca tttgtacggc tccgcagtg atggcggcct gaagccacac agtgatattg 1500
atttctggt tacggtgacc gtaaggcttg atgaaacaac gggcgagct ttgatcaacg 1560
accttttgg aacttcggct tcccctggag agagcgagat tctccgcgt gtagaagtca 1620
ccattgttgt gcacgacgac atcattccgt ggcgttatcc agctaagcgc gaactgcaat 1680
ttggagaatg gcagcgcaat gacattcttg caggtatctt cgagccagcc acgatcgaca 1740
ttgatctggc tatcttgctg acaaaaagcaa gagaacatag cgttgccctg gtaggtccag 1800
cggcggagga actctttgat ccggttctcg aacaggatct atttgagcgc ctaaatgaaa 1860
ccttaacgct atggaactcg ccgccgact gggctggcga tgagcgaat gtagtctta 1920
cgttgtcccg catttggtac agcgcagtaa ccggcaaat cgcgccgaag gatgtcgtg 1980
ccgactgggc aatggagcgc ctgccggccc agtatcagcc cgtcactatt gaagctaggc 2040
aggcttatct tggacaagaa gatcgcttgg cctcgcgcg agatcagttg gaagaatttg 2100
ttcactacgt gaaaggcgag atcaccaagg tagtcggcaa ataaagctct agtggatccc 2160
cgaggaaatc gcgtgacggt cgcaaaccat ccggcccggt acaaatcggc gcggcgctgg 2220

```

```

gtgatgacct ggtggagaag ttgaaggcgc cgcaggccgc ccagcggcaa cgcacgagg 2280
cagaagcacg ccccggtgaa tcgtggcaag cggccgctga tcgaatccgc aaagaatccc 2340
ggcaaccgcc ggcagccggt gcgcgcgcga ttaggaagcc gcccaagggc gacgagcaac 2400
cagatttttt cgttccgatg ctctatgacg tgggcacccg cgatagtcgc agcatcatgg 2460
acgtggccgt tttccgtctg tcgaagcgtg accgacgagc tggcgagggtg atccgctacg 2520
agcttccaga cgggcacgta gaggtttcag cagggccggc cggcatggcc agtgtgtggg 2580
attacgacct ggtactgatg gcggtttccc atctaaccga atccatgaac cgataccggg 2640
aagggaaggg agacaagccc ggccgcgtgt tccgtccaca cgttgccggc gtactcaagt 2700
tctgccggcg agccgatggc ggaaagcaga aagacgacct ggtagaaacc tgcattccgt 2760
taaaccaccac gcacgttgcc atgcagcgtg cgaagaaggc caagaacggc cgcctggtga 2820
cgggtatccga ggtggaagcc ttgattagcc gctacaagat cgtaaagagc gaaaccgggc 2880
ggccggagta catcgagatc gagctagctg attggatgta ccgcgagatc acagaaggca 2940
agaaccggga cgtgctgacg gttcaccccg attacttttt gatcgatccc ggcacccggc 3000
gttttctcta ccgcctggca cgcgcgcgcg caggcaaggc agaagccaga tggttgttca 3060
agacgatcta cgaacgcagt ggcagcgcgc gagagttaa gaagttctgt ttcaccgtgc 3120
gcaagctgat cgggtcaaat gacctgccgg agtacgattt gaaggaggag gcggggcagg 3180
ctggcccgat cctagtcatg cgctaccgca acctgatcga gggcgaagca tccgccggtt 3240
cctaattgtac ggagcagatg ctagggcaaa ttgccctagc aggggaaaaa ggtcgaaaag 3300
gtctctttcc tgtggatagc acgtacattg ggaacccaaa gccgtacatt ggggaaccga 3360
acccgtacat tgggaaccca aagccgtaca ttgggaaccg gtcacacatg taagtgactg 3420
atataaaaga gaaaaaaggc gatttttccg cctaaaaactc tttaaaactt attaaaactc 3480
ttaaaacccg cctggcctgt gcataactgt ctggccagcg cacagccgaa gagctgcaaa 3540
aagcgcctac ccttcggtcg ctgcgcctcc tacgccccgc cgcttcgcgt cggcctatcg 3600
cggccgctgg ccgctcaaaa atggctggcc tacggccagg caatctacca gggcgccggc 3660
aagccgcgcc gtcgccactc gaccgcggcg gctgaggtct gcctcgtaga gaagggtgtg 3720
ctgactcata ccaggcctga atcgccccat catccagcca gaaagtgagg gagccacggt 3780
tgatgagagc tttgtttagt gtggaccagt tggatgtttt gaacttttgc tttgccacgg 3840
aacggtctgc gttgtcggga agatgcgtga tctgacctt caactcagca aaagttcgat 3900
ttattcaaca aagccgcgt cccgtcaagt cagcgtaatg ctctgccagt gttacaacca 3960
attaaccaat tctgattaga aaaactcatc gagcatcaaa tgaactgca atttattcat 4020
atcaggatta tcaataccat atttttgaaa aagccgtttc tgtaatgaag gagaaaactc 4080
accgaggcag ttccatagga tggcaagatc ctggtatcgg tctgcgattc cgactcgtcc 4140
aacatcaata caacctatta atttcccctc gtcaaaaata aggttatcaa gtgagaaatc 4200
accatgagtg acgactgaat ccggtgagaa tggcaaaagc tctgcattaa tgaatcggcc 4260
aacgcgcggg gagaggcggg ttgcgtattg ggcgctcttc cgcttcctcg ctcaactgact 4320
cgctgcgctc ggtcgttcgg ctgcggcgag cggatcagc tcaactcaaag gcggtaatatc 4380
ggttatccac agaatacagg gataacgcag gaaagaacat gtgagcaaaa ggccagcaaa 4440
aggccaggaa ccgtaaaaag gccgcgttgc tggcggtttt ccataggctc cgccccctg 4500
acgagcatca caaaaatcga cgctcaagtc agagggtggc aaacccgaca ggactataaa 4560
gataccaggc gtttccccct ggaagctccc tcgtgcgctc tctgttccg accctgccgc 4620
ttaccggata cctgtccgcc tttctccctt cgggaagcgt ggcgctttct caatgctcac 4680
gctgtaggta tctcagttcg gtgtaggtcg ttcgctccaa gctgggctgt gt 4732

```

<210> 6

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: HiNK025bis

<400> 6

caattaccat ggacacggtc gtgg

24

<210> 7
<211> 30
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: HiNK226

<400> 7
gccaaatggt tgaacgctgc agcctatttg

30

<210> 8
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: HiNK025bis2

<400> 8
aatcgtccat ggatacggtc gtgg

24

<210> 9
<211> 30
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: HiNK226bis

<400> 9
ctagggccgg gttcctctgc agcctatttg

30

<210> 10
<211> 31
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: HiNK251

<400> 10
ctcccagggt gagactgccc tgcagtgccc a

31

<210> 11
<211> 26
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: HiNK228

<400> 11

ttaccatgca tacggtcgtg ggtagg

26

<210> 12

<211> 26

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: HiNK228bis

<400> 12

cgttaatgca tacggtcgtg ggtagg

26

<210> 13

<211> 3338

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: BWVYV duplex
RNA gene

<220>

<221> promoter

<222> (1)..(1131)

<223> RolC promoter

<220>

<221> repeat_unit

<222> (1132)..(1737)

<223> BWVYV CP inverted repeat fragment

<220>

<221> stem_loop

<222> (1738)..(2470)

<223> 0.7 Kb spacer fragment downstream of BWVYV CP gene

<220>

<221> repeat_unit

<222> (2471)..(3074)

<223> BWVYV CP inverted repeat fragment

<220>

<221> terminator

<222> (3076)..(3338)

<223> NOS terminator

<400> 13

ggatccggcg tcggaaactg ggcaccaatca gacacagtct ctggtcggga aagccagagg 60
 tagtttggca acaatcacat caagatcgat ggcgaagaca cgggaggcct taaaatctgg 120
 atcaagcgaa aatactgcat gcgtgatcgt tcatgggttc atagtactgg gtttgctttt 180
 tcttgcgtg ttgtttggcc ttagcgaaag gatgtcaaaa aaggatgcc ataattggga 240
 ggagtggggg aaagcttaaa gttggccgc tattggattt cgcgaaagcg cattggcaaa 300

```

cgtgaagatt gctgcattca agatactttt tctattttct ggtaagatg taaagtattg 360
ccacaatcat attaattact aacattgtat atgtaataata gtgoggaaat tatctatgcc 420
aaaatgatgt attaataata gcaataataa tatgtgttaa tctttttcaa tcgggaatac 480
gtttaagcga ttatcgtgtt gaataaatta ttccaaaagg aaatacatgg ttttgagaa 540
cctgctatag atatatgcc aatttact agtttagtgg gtgcaaaact attatctctg 600
tttctgagtt taataaaaaa taaataagca ggcgaatag cagttagcct aagaaggaa 660
ggtggccatg tacgtgcttt taagagaccc tataataaat tgccagctgt gttgctttgg 720
tgccgacagg cctaacgtgg ggtttagctt gacaaagtag cgcctttccg cagcataaat 780
aaaggtaggc ggtgctgcc cattattaaa ggaaaagca aaagctgaga ttccatagac 840
cacaaaccac cattattgga ggacagaacc tattccctca cgtgggtcgc tgagctttaa 900
acctaaatag taaaaacaat taaaagcagg caggtgtccc ttctatattc gcacaacgag 960
gcgacgtgga gcatcgacag ccgcatccat taattaataa atttgtggac ctatacctaa 1020
ctcaaatatt tttattattt gctccaatac gctaagagct ctggattata aatagtttg 1080
atgcttcgag ttatgggtac aagcaacctg ttccctactt tgttaccatg gacacggctg 1140
tggttaggag aattatcaat ggaagaagac gaccacgcag gcaaacacga cgcgctcagc 1200
gccctcagcc agtgggtgtg gtccaaacct ctgggcaac acaacgccga cctagacgac 1260
gacgaagagg taacaaccgg acaggaagaa ctgttcctac cagaggagca ggttcgagcg 1320
agacatttgt tttctcaaaa gacaatctcg cgggaagttc cagcggagca atcacgttcg 1380
ggcogagtc atcagactgc ccggcattct ctaatggaat gctcaaggcc taccatgagt 1440
ataaaatctc aatggtcatt ttggagtctg tctccgaagc ctcttcccaa aattccggtt 1500
ccatcgctta cgagctggac ccacactgta aactcaactc cctttcctca actatcaaca 1560
agttcgggat cacaaagccc gggaaaagg cgtttacagc gtcttacatc aacggaacgg 1620
aatggcacga cgttgccgag gaccaattca ggatcctcta caaaggcaat ggttcttcat 1680
cgatagctgg ttctttcaga atcaccatta agtgcaatt ccacaacccc aaataggctg 1740
cagtgcctaa ctctctttgg tctttctgtc ttacgggaac cggatgagcc ttgttcatca 1800
agtgtatagg cgatcatccc tatctccatc atccgatctg tccaggctcc gtacgaaacg 1860
gogtaattat atttagattg cttctggaca ggggtccaa caacaaagaa ggaggcattg 1920
tcaccagtcg tcttgatag acaagtcaaa tctccatctc tttccagaca ctgtccttga 1980
ttgaaatgac agccattgag ttccatgtct ggtgggcat acttcaaagt attatcgcc 2040
ttgtgttgg ttatctccac attattgtaa atccccacgt tccaaccttc actaagatca 2100
tcgtttagg cgatgagacc atcttgtttg tcttgttag gatctgtggt gcttgagggt 2160
ggttgatacc cctccatcga tatttccacg gtccactcac cttgagggac tggcactatt 2220
atcatcgga tggctttcaa agaattctgg gaataccatc gagaatcgag gttcgtccag 2280
ttcatgttct cgtcctctat gtagcgaaac cgttgggacg gcatatcata caaagagatg 2340
gcatcatccg tagattgagc cattatacga gtcacgggga ctccagtata gacgataaaa 2400
cgatatttct tttgggtgtt ggttgtgga gagggagaag gccctgggct agggcgggt 2460
tctcgtctc cctatttggg gttgtggaat tgacacttaa tgggtattct gaaagaacca 2520
gctatcgatg aagaaccatt gcctttgtag aggatcctga attggtctc ggcaacgtcg 2580
tgccattccg ttccgttgat gtaagacgct gtaaacgccc ttttccggg ctttgtgatc 2640
ccgaacttgt tgatagttga ggaaagggag ttgagtttac agtgtgggtc cagctcgtaa 2700
gogatggaac cggaattttg ggaagaggct tcggagacga actccaaaat gaccattgag 2760
attttatact catggtaggc cttgagcatt ccattagaga atgcccggca gtctgataga 2820
ctcggcccg aactgattgc tccgctggaa cttcccgca gattgtctt tgagaaaaca 2880
aatgtctcgc tcgaacctgc tctctgtgta ggaacagttc ttctgtcgc gttgttacct 2940
cttgcgtcgc gtctaggctg cgttgtgtt gcccgagagg tttggaccac aaccactggc 3000
tgagggcgct gagcgctcg tgtttgcctg cgtggtcgtc ttcttccatt gataattctc 3060
ctaccacga ccgtatgcag atcgttcaaa catttggcaa taaagtctt taagattgaa 3120
tctgttgcc ggtcttgca tgattatcat ataattctg ttgaattacg ttaagcatgt 3180
aataattaac atgtaatgca tgacgttatt tatgagatgg gtttttatga ttagagtccc 3240
gcaattatac atttaatacg cgatagaaaa caaaatatag cgcgcaacct aggataaatt 3300
atcgcgcgcg gtgtcatcta tgttactaga tctctaga 3338

```

<210> 14

<211> 29

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: HiNK285

<400> 14

tcgtagaaga gaattcaccc aaactatcc

29

<210> 15

<211> 29

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: HiNK283

<400> 15

aagaattgca ggatccacag gctcggtac

29

<210> 16

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: HiNK284

<400> 16

ttccaacgaa ttcggtctca gaca

24

<210> 17

<211> 3648

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: pHINK181

<220>

<221> promoter

<222> (1)..(1738)

<223> ubiquitin 3 promoter plus intron

<220>

<221> repeat_unit

<222> (1739)..(2166)

<223> BNYVV RNA1 repeat fragment

<220>

<221> misc_feature

<222> (2167)..(2946)

<223> spacer fragment

<220>
 <221> repeat_unit
 <222> (2947)..(3375)
 <223> ENYVW RNA1 repeat fragment

 <220>
 <221> stem_loop
 <222> (1739)..(3375)
 <223> Inverted repeat of ENYVW RNA1 fragment separated
 by spacer

 <220>
 <221> terminator
 <222> (3376)..(3648)
 <223> NOS terminator

<400> 17

```

ggtaccggat ttggagccaa gtctcataaa cgccattgtg gaagaaagtc ttgagttggt 60
ggaatgtaa cagagtagta agaacagaga agagagagag tgtgagatac atgaattgtc 120
gggcaacaaa aatcctgaac atcttatttt agcaaagaga aagagttccg agtctgtagc 180
agaagagtga ggagaaattht aagctcttgg acttgtgaat tgttccgcct cttgaatact 240
tcttcaatcc tcatatattc ttcttctatg ttacctgaaa accggcattt aatctcgcgg 300
gtttattccg gttcaacatt ttttttgttt tgagttatta tctgggctta ataacgcagg 360
cctgaaataa attcaaggcc caactgtttt tttttttaag aagttgctgt taaaaaaaaa 420
aaaagggaat taacaacaac aacaaaaaaaa gataaagaaa ataataacaa ttactttaat 480
tgtagactaa aaaaacatag attttatcat gaaaaaaaga gaaaagaaat aaaaacttgg 540
atcaaaaaaa aaaacataca gatcttctaa ttattaactt ttcttaaaaa ttaggtcctt 600
tttcccaaca attaggttta gagttttgga attaaaccaa aaagattggt ctaaaaaata 660
ctcaaatttg gtagataagt ttcttatttt taattagtca atggtagata cttttttttc 720
ttttctttat tagagtagat tagaatcttt tatgccagt tttgataaat taaatcaaga 780
agataaacta tcataatcaa catgaaatta aaagaaaaat ctcatatata gtattagtat 840
tctctatata tattatgatt gcttattctt aatgggttgg gttaaccaag acatagtctt 900
aatggaaaga atcttttttg aactttttcc ttattgatta aattcttcta tagaaaagaa 960
agaaattatt tgaggaaaag tatatacaaa aagaaaaata gaaaaatgtc agtgaagcag 1020
atgtaatgga tgacctaatc caaccaccac cataggatgt ttctacttga gtcggtcttt 1080
taaaaacgca cgggtgaaaa tatgacacgt atcatatgat tccttctttt agtttcgtga 1140
taataatcct caactgatat ctctcttttt ttgttttggc taaagatatt ttattctcat 1200
taatagaaaa gacggttttg ggcttttggg ttgcgatata aagaagacct tcgtgtggaa 1260
gataataatt catcctttcg tctttttctg actcttcaat ctctcccaa gcctaaagcg 1320
atctctgcaa atctctcgcg actctctctt tcaaggata ttttctgatt ctttttgttt 1380
ttgattcgta tctgatctcc aatttttgtt atgtggatta ttgaatcttt tgtataaatt 1440
gcttttgaca atattgttcg ttctgtcaat ccagcttcta aattttgtcc tgattactaa 1500
gatatcgatt cgtagtgttt acatctgtgt aatttcttgc ttgattgtga aattaggatt 1560
ttcaaggacg atctattcaa tttttgtgtt ttctttgttc gattctctct gttttagggt 1620
tcttatgttt agatccgttt ctctttgttg ttgttttgat ttctcttacg gcttttgatt 1680
tggtatatgt tcgctgattg gtttctactt gttctattgt tttatttcag gtggatccac 1740
aggctcggta cttatttcga aaagtggaga attctccatc atcgacacaa gatagtgttg 1800
cacgtatggt tgcctagcta tttgtttctg attgtttggt gccaaatgta gctgatactt 1860
tttctgcttc caatttgtgg cgaattatgg acaaagctat gcatgacatg gtcgcaaaaa 1920
attaccaagg ccaaatggaa gaggagttha cgcgtaatgc taaactatat cgttttcagt 1980
tgaaggatat tgaaaaacct ttgaaggacc cagagactga tttggcaaaag gctggtcaag 2040
ggatattggc atggtctaag gaggcacatg ttaagtttat ggttgctttt agagttttta 2100
atgatttgtt attgaagtca taaactcta atgttgttta cgataacaca atgtctgaga 2160
ccgaattcac caaaactatc ctcaacgggt ggcaatgaca taaaaacttc ccgtatcggg 2220
aacatcatca taaattgttc acgcccatt cgagacacag agataatagc atccaaccaa 2280
cgttgaacat catcaacatt gcgacaagat aagctagcgt tacactccaa aaaatcagca 2340

```

```

taaacagctg ggtctttggg aagattttta atccaatcac gcaaagattc ctggtattca 2400
caaaaatgct tatactcacg gaacctgtgt gctgctatct tcgtcaattt acgcgaaaca 2460
cttggaaca aatgtccatt agataaagca taaccacaaa aagtgatagg aacattttaa 2520
tccaatttga aatccaagac agtttccttt ttaatcaact ttaacatttg atcgttaatt 2580
ttcaaattag cctgcctttt aaaaccatca tcgcccttca tggccataca aaatgggtcg 2640
gtcccacgaa gcatagcatt taacatagca cccattaaaa tgggtattacc aagcaaagtg 2700
cggggttctc cactagtctt aacataagac atatgtgctc tgacatatct ggactgcata 2760
acatatttct cagcaaatga gaaataccaa tccaaaaaga agtcagaaat gcccaaagca 2820
gcataaatat gtctttctat caattgggtg aaaacccctt gcccagaatc gcaagcagca 2880
gcatcgataa ccccgtttat agcactatct ggtactgtat tcatggcggc atttattttt 2940
ccaacaaatt cgggtctcaga cattgtgtta togtaaacaa cattagagtt taatgacttc 3000
aataacaaat catttaaaac tctaaaagca accataaact taacatgtgc ctcttagac 3060
catgccaaata tcccttgacc agcctttgcc aaatcagtct ctgggtcctt caaagggttt 3120
tcaatatect tcaactgaaa acgatatagt ttagcattac gcgtaaactc ctcttcatt 3180
tggccttggt aattttttgc gaccatgtca tgcatagtt tgtccataat tcgccacaaa 3240
ttggaagcag aaaaagtatc agctacattt ggcaccaaac aatcagaaac aaatagctga 3300
gcaaccatac gtgcaacact atcttgtgtc gatgatggag aatttctcac ttttcgaaat 3360
aagtaccgag cctgtggatc ccccgaaatt ccccgatcgt tcaaacattt ggcaataaag 3420
tttcttaaga ttgaatcctg ttgccggctc tgcgatgatt atcatcta atctgttgaa 3480
ttacgttaag catgtaataa ttaacatgta atgcatgacg ttatttatga gatgggtttt 3540
tatgattaga gtcccgaat tacaattta atacgcgata gaaaacaaaa tatagcgcgc 3600
aaactaggat aaattatcgc gcgcggtgtc atctatgtta ctagatcc 3648

```

<210> 18

<211> 3648

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: pHiNK184

<220>

<221> promoter

<222> (1)..(1738)

<223> ubiquitin 3 promoter plus leader intron

<220>

<221> repeat_unit

<222> (1739)..(2166)

<223> BNYVV RNA1 repeat fragment

<220>

<221> misc_feature

<222> (2167)..(2946)

<223> spacer

<220>

<221> repeat_unit

<222> Complement((2947)..(3375))

<223> BNYVV RNA1 repeat fragment

<220>

<221> stem_loop

<222> (1739)..(3375)

<223> Inverted repeat of BNYVV RNA1 fragment separated

by spacer

<220>

<221> terminator

<222> (3376)..(3648)

<223> NOS terminator

<400> 18

```

ggtaccggat ttggagccaa gtctcataaa cgccattgtg gaagaaagtc ttgagttggt 60
ggtaatgtaa cagagtagta agaacagaga agagagagag tgtgagatac atgaattgtc 120
gggcaacaaa aatcctgaac atcttatttt agcaaagaga aagagttccg agtctgtagc 180
agaagagtga ggagaaattt aagctcttgg acttgtgaat tgttccgcct cttgaatact 240
tcttcaatcc tcataatattc ttcttctatg ttacctgaaa accggcattt aatctcgcgg 300
gtttattccg gttcaacatt ttttttgttt tgagttatta tctgggctta ataacgcagg 360
cctgaaataa attcaaggcc caactgtttt tttttttaag aagttgctgt taaaaaaaaa 420
aaaaggggat taacaacaac aacaaaaaaaa gataaagaaa ataataacaa ttactttaat 480
tgtagactaa aaaaacatag attttatcat gaaaaaaga gaaaagaaat aaaaacttgg 540
atcaaaaaaa aaacataca gatcttctaa ttattaactt ttcttaaaaa ttaggtcctt 600
tttccaaca attaggttta gagttttgga attaaacca aaagattggt ctaaaaata 660
ctcaaatttg gtagataagt ttcttattt taattagtca atggtagata ctttttttcc 720
ttttctttat tagagtagat tagaatcttt tatgccagt ttgataaat taaatcaaga 780
agataaacta tcataatcaa catgaaatta aaagaaaaat ctcatatata gtattagtat 840
tctctatata tattatgatt gcttattctt aatgggttgg gttaaccaag acatagtctt 900
aatggaaaga atcttttttg aactttttcc ttattgatta aattcttcta tagaaaagaa 960
agaaattatt tgaggaaaag tatatacaaa aagaaaaata gaaaaatgtc agtgaagcag 1020
atgtaatgga tgacctaatc caaccaccac cataggatgt ttctacttga gtcggctctt 1080
taaaaacgca cgggtgaaaa tatgacacgt atcatatgat tccttccttt agtttcgtga 1140
taataatcct caactgatat ctctcctttt ttgttttggc taaagatatt ttattctcat 1200
taatagaaaa gacggttttg ggcttttggg ttgcatata aagaagacct tcgtgtggaa 1260
gataataatt catcctttcg tctttttctg actcttcaat ctctcccaa gcctaaaagcg 1320
atctctgcaa atctctcgcg actctctctt tcaaggata ttttctgatt ctttttgttt 1380
ttgattcgta tctgatctcc aatttttgtt atgtggatta ttgaatcttt tgtataaatt 1440
gcttttgaca atattgttcg ttctgtcaat ccagcttcta aattttgtcc tgattactaa 1500
gatatcgatt cgtagtgttt acatctgtgt aatttcttgc ttgattgtga aattaggatt 1560
ttcaaggacg atctattcaa tttttgtgtt ttctttgttc gattctctct gtttttaggt 1620
tcttatgttt agatccgttt ctctttgggt ttgttttgat ttctcttacg gcttttgatt 1680
tggtatatgt tcgctgattg gtttctactt gttctattgt ttattttcag gtggatccac 1740
aggctcggtg ctatttcga aaagtgaaga attctccatc atcgacacaa gatagtgttg 1800
cacgtatggt tctcagcta ttgtttctg atgtttggg gccaaatgta gctgatactt 1860
tttctgcttc caatttggg cgaattatgg acaaagctat gcatgacatg gtcgcaaaaa 1920
attaccaagg ccaaatggaa gaggagttta cgcgtaatgc taaactatat cgttttcagt 1980
tgaaggatat tgaaaaacct ttgaaggacc cagagactga tttggcaaag gctggtcaag 2040
ggatattggc atggtctaag gaggcacatg ttaagtttat ggttgccttt agagttttaa 2100
atgatttggt attgaagtca ttaaactcta atgttgttta cgataacaca atgtctgaga 2160
ccgaatttgt tggaaaaata aatgccgcc tgaatacagt accagatagt gctataaacg 2220
gggttatcga tgctgctgct tgcgattctg ggcaaggggt tttcacccaa ttgatagaaa 2280
gacatattta tgctgcttgg ggcatttctg acttcttttt ggattggtat ttctcatttc 2340
gtgagaaata tgttatgcag tccagatatg tcagagcaca tatgtcttat gttaagacta 2400
gtggagaacc cggcactttg cttggtaata ccattttaat ggggtgctatg ttaaatgcta 2460
tgcttcgtgg gaccggacca ttttgtatgg ccatgaagg cgatgatggt tttaaaaggc 2520
aggctaattt gaaaattaac gatcaaatgt taaagttgat taaaaggaa actgtcttgg 2580
atttcaaatt ggatttaaat gttcctatca ctttttgggt ttatgcttta tctaaggac 2640
atttgtttcc aagtgtttcg cgtaaattga cgaagatagc agcacacagg ttccgtgagt 2700
ataagcattt ttgtgaatac caggaatctt tgcgtgattg gattaaaaat cttcccaaag 2760
accagctgt ttatgctgat tttttggagt gtaacgctag cttatcttgt cgcaatgttg 2820
atgatgttca acgttgggtg gatgctatta tctctgtgtc tcgaatcggg cgtgagcaat 2880

```

```

ttatgatgat gttcccgata cgggaagttt ttatgtcatt gccacccgtt gaggatagtt 2940
tgggtgaatt cggcttcaga cattgtgtta tcgtaaaca cattagagtt taatgacttc 3000
aataacaaat catTTAAAAC tctaaaagca accataaact taacatgtgc ctcccttagac 3060
catgccaaata tcccttgacc agcctttgcc aaatcagtct ctgggtcctt caaaggTTTT 3120
tcaatatcct tcaactgaaa acgatatagt ttagcattac gcgtaaactc ctcttccatt 3180
tggccttggg aatTTTTTgc gaccatgtca tgcatagtct tgtccataat tcgccacaaa 3240
ttggaagcag aaaaagtatc agctacattt ggcaccaaac aatcagaaac aaatagctga 3300
gcaaccatac gtgcaacact atcttgtgtc gatgatggag aatttctcac ttttcgaaat 3360
aagtaccgag cctgtggatc ccccgattt cccgatcgt tcaaacattt ggcaataaag 3420
tttcttaaga ttgaatcctg ttgccgtctc tgcgatgatt atcatctaata ttctgttgaa 3480
ttacgttaag catgtaataa ttaacatgta atgcatgacg ttatttatga gatgggtttt 3540
tatgattaga gtcccgcaat tatacattta atacgcgata gaaaacaaaa tatagcgcgc 3600
aaactaggat aaattatcgc gcgcgggtgc atctatgtta ctagatcc 3648

```

<210> 19

<211> 41

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: ZUP1563

<400> 19

```

gggcggatcc gctagccgc gccgctctt tctttccaag g 41

```

<210> 20

<211> 35

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: ZUP1564

<400> 20

```

cccgccatgg gtcgacgcc ttttttatga gctgc 35

```

<210> 21

<211> 40

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: ZUP1565

<400> 21

```

cccgccatgg gatccgatga tttctaccga gaattaaggg 40

```

<210> 22

<211> 29

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: ZUP1566

<400> 22

gggcgctagc ctaatgctta tatagtacc

29

<210> 23

<211> 30

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: ZUP1567

<400> 23

gggcgctagc cttgctggag tataagccgg

30

<210> 24

<211> 35

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: ZUP1568

<400> 24

gggcgtcgac cgccgggcttt aaaggtggga ggccc

35

<210> 25

<211> 12766

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: pZU623

<220>

<221> promoter

<222> (55)..(1781)

<223> ubiquitin3 promoter plus leader intron

<220>

<221> misc_feature

<222> (1790)..(2430)

<223> PRSV nt CP region

<220>

<221> misc_feature

<222> (2511)..(3111)

<223> ZYMV nt CP region

<220>

<221> intron

<222> (3245)..(3686)
<223> actin2 intronL

<220>
<221> misc_feature
<222> Complement((3822)..(4422))
<223> ZYMV nt CP region

<220>
<221> misc_feature
<222> Complement((4503)..(5143))
<223> PRSV nt CP region

<220>
<221> terminator
<222> (5160)..(5429)
<223> NOS terminator

<220>
<221> promoter
<222> (5498)..(6669)
<223> SMAS promoter

<220>
<221> gene
<222> (6691)..(7866)
<223> phosphomannose isomerase A coding sequence

<220>
<221> terminator
<222> (7928)..(8202)
<223> nopaline synthase terminator

<220>
<221> misc_feature
<222> (8254)..(8385)
<223> nopaline left border fragment

<220>
<221> gene
<222> (8664)..(9452)
<223> spectinomycin (aadA) coding sequence

<220>
<221> misc_structure
<222> (9462)..(11549)
<223> pVS1 ORI

<220>
<221> misc_structure
<222> (11550)..(12484)
<223> pUC19 ORI

<220>
<221> misc_feature
<222> (12500)..(12755)

<223> nopaline right border region

<220>

<221> stem_loop

<222> (1790)..(5143)

<223> PRSV-ZYMV inverted repeat fragment

<400> 25

```

ggccgcagcg gccatttaaa tcaattgggc ggcgcgaatt cgagctcggg accccggatt 60
tggagccaag tctcataaac gccattgtgg aagaaagtct tgagttgggt gtaatgtaac 120
agagtagtaa gaacagagaa gagagagagt gtgagataca tgaattgtcg ggcaacaaaa 180
atcctgaaca tcttatttta gcaaagagaa agagttccga gtctgtagca gaagagtggag 240
gagaaattta agctcttgga cttgtgaatt gttccgcctc ttgaatactt cttcaatcct 300
catatattct tcttctatgt tacctgaaaa ccggcattta atctgcggg tttattccgg 360
ttcaacattt tttttgtttt gagttattat ctgggcttaa taacgcaggc ctgaaataaa 420
ttcaaggccc aactgttttt tttttaagaa gttgctgtta aaaaaaaaaa aagggaatta 480
acaacaacaa caaaaaaga taaagaaaat aataacaatt actttaattg tagactaaaa 540
aaacatagat tttatcatga aaaaaagaga aaagaataa aaacttggat caaaaaaaaa 600
aacatacaga tcttctaatt attaaacttt cttaaaaatt aggtcctttt tcccaacaat 660
taggttttaga gttttggaat taaacaaaa agattgttct aaaaaatact caaatttggg 720
agataagttt ccttatttta attagtcaat ggtagatact ttttttctt tctttatta 780
gagtagatta gaatctttta tgccaagttt tgataaatta aatcaagaag ataaactatc 840
ataatcaaca tgaaattaaa agaaaaatct catatatagt attagtattc tctatatata 900
ttatgattgc ttattcttaa tgggttgggt taaccaagac atagtcttaa tggaaagaat 960
cttttttgaa ctttttcctt attgattaaa ttcttctata gaaagaaaag aaattatttg 1020
agggaaaagta tatacaaaaa gaaaaataga aaaatgtcag tgaagcagat gtaatggatg 1080
acctaatacca accaccacca taggatgttt ctacttgagt cggctcttta aaaacgcacg 1140
gtggaaaata tgacacgtat catatgatct cttcctttag tttcgtgata ataactctca 1200
actgatatct tccttttttt gttttggcta agatatattt attctcatta atagaaaaaga 1260
cggttttggg cttttgggtt gcgatataaa gaagaccttc gtgtggaaga taataattca 1320
tcctttcgtc tttttctgac tcttcaatct ctcccaaagc cttaaagcag ctctgcaaat 1380
ctctcgcgac tctctcttc aaggtatatt ttctgattct ttttgtttt gattcgtatc 1440
tgatctccaa tttttgttat gtggattatt gaatctttt tataaattgc ttttgacaat 1500
attgttcgtt tcgtcaatcc agcttctaaa ttttgcctg attactaaga tatcgattcg 1560
tagtgtttac atctgtgtaa tttcttgctt gattgtgaaa ttaggatttt caaggacgat 1620
ctattcaatt tttgtgtttt ctttgttcga ttctctctgt tttaggtttc ttatgtttag 1680
atccgtttct ctttgggtgt gttttgattt ctcttacggc ttttgatttg gtatatgttc 1740
gctgattggg ttctacttgt tctattgttt tatttcaggg gggggatccg atgatttcta 1800
ccgagaatta agggaaagac tgtccttaat ttaaatcacc ttcttcagta taatccgcaa 1860
caaattgaca tttctaacac tcgtgccact cagtcacaat ttgagaagtg gtatgaggga 1920
gtgaggaatg attatggtct caatgataat gaaatgcaag tgatgctaaa tggcttgatg 1980
gtttgggtga tcgagaatgg tacatctcca gacatatctg gtgtctgggt tatgatggat 2040
ggggaaaccc aagttgatta tccaatcaag cctttaatag agcatgctac tccgtcattt 2100
aggcaaatga tggctcactt tagtaacgcg gcagaagcat acattgcgaa gagaaatgct 2160
actgagagat acatgcgcg gtatggaatc aagagaaatt tgactgacat tagtcttgct 2220
agatacgctt tcgacttcta tgaggtgaat tcgaaaacac ctgatagggc tcgtgaagct 2280
cacatgcaga tgaaagctgc agcgctgcga aacactagtc gcagaatgtt tggatggac 2340
ggcagtggtt gtaacaagga agaaaacacg gagagacaca cagtgggaaga tgtcaataga 2400
gacatgcact ctctcctggg tatgcgcaac tgaatactcg cgcttggtgt tttgtcgagt 2460
ctgactcgac cctgtttcac cttatggtac tatataagca ttaggctagc cttgctggag 2520
tataagccgg atcaaattga gttatacaac acacgagcgt ctcatcagca attgcctct 2580
tggttcaacc aagttaaaac agaatatgat ctgaatgagc aacagatggg agttgtaatg 2640
aatggtttca tggtttgggt cattgaaaat ggcacgtcac ccgacattaa cggagtatgg 2700
gttatgatgg acggtaatga gcagggtgaa tatcctttga aaccaatagt tgaaaatgca 2760
aagccaacgc tcgcacaaat aatgcatcac ttttcagatg cagcggaggc atatatagag 2820
atgagaaatg cagaggcacc atacatgccg aggtatggtt tgcttcgaaa cttacgggat 2880

```

```

aggagtttgg cacgatatgc tttcgacttc tacgaagtca attccaaaac tccggaaaga 2940
gcccgcggaag ctgttgcgca gatgaaagca gcagccctta gcaatgtttc ttcaagggtg 3000
tttggccttg atggaaatgt tgccaccact agcgaagaca ctgaacggca cactgcacgt 3060
gatgttaata ggaacatgca caccttgcta ggtgtgaata caatgcagta aagggtaggt 3120
cgctaccta ggttatcggt tcgctgccga cgtaattcta atatttaccg ctttatgtga 3180
tgtctttaga tttctagagt gggcctccca cctttaaagc ccgcgccgcg tctttcttcc 3240
caaggtaata ggaactttct ggatctactt tatttgctgg atctcgatct tgttttctca 3300
atttccttga gatctggaat tcgtttaatt tggatctgtg aacctccact aaatcttttg 3360
gttttactag aatcgatcta agttgaccga tcagttagct cgattatagc taccagaatt 3420
tggcttgacc ttgatggaga gatccatggt catgttacct gggaaatgat ttgtatatgt 3480
gaattgaaat ctgaactggt gaagttagat tgaatctgaa cactgtcaat gttagattga 3540
atctgaacac tgtttaagtt agatgaagtt tgtgtataga ttcttcgaaa ctttaggatt 3600
tgtagtgctg tacgttgaaac agaaagctat ttctgattca atcagggttt atttgactgt 3660
attgaactct ttttgtgtgt ttgcagctca taaaaaatgg cgtcgaccgc gggctttaaa 3720
gggtgggagc ccactctaga aatctaaaga catcacataa agcggtaaat attagaatta 3780
cgtcggcagc gaaacgataa cctaggtagg cgacctacc tttactgcat tgtattcaca 3840
cctagcaagg tgtgcatggt cctattaaca tcacgtgcag tgtgccgttc agtgtcttcg 3900
ctagtgggtg caacatttcc atcaaggcca aacaaccttg aagaaacatt gctaagggtc 3960
gctgctttca tctgcgcaac agcttcgagg gctctttccg gagttttgga attgacttcg 4020
tagaagtcga aagcatatcg tgccaaactc ctatcccgta agtttcgaag caaaccatac 4080
ctcggcatgt atgggtcctc tgcatttctc atctctatat atgcctccgc tgcactgaa 4140
aagtgatgca ttatttgctg cagcgttggc tttgcatttt caactattgg tttcaaagga 4200
tattcaacct gtcattacc gtccatcata acccatactc cgttaatgtc gggtgacgtg 4260
ccattttcaa tgcaccaaac catgaaacca ttcattacaa ctcccatctg ttgctcattc 4320
agatcataatt ctgttttaac ttggttgaac caagaggcga attgctgatg agacgctcgt 4380
gtgttggtata actcaatttg atccggctta tactccagca aggctagcct aatgcttata 4440
tagtaccata aggtgaaaca ggttcgagtc agactcgaca aacacacaag cgcgagtatt 4500
cagttgcgca taccaggag agagtgcag tctctattga catcttcac tgtgtgtctc 4560
tccgtgtttt ctctctgtt actaacactg ccgtccatac caaacattct gcgactagt 4620
tttcgcagcg ctgcagcttt catctgcag tgagcttcac gagccctatc aggtgttttc 4680
gaattcacct catagaagtc gaaagcgtat ctagcaagac taatgtcagt caaatttctc 4740
ttgattccat accgcggcat gtatctctca gtagcatttc tcttcgcaat gtatgcttct 4800
gccgcgttac taaagtgagc cataatttgc ctaaatgacg gagtagcatg ctctattaaa 4860
ggcttgattg gataatcaac ttgggtttcc ccatccatca taaccagac accgatatg 4920
tctggagatg taccattctc gatacaccaa accatcaagc catttagcat cacttgcat 4980
tcattatcat tgagaccata atcattctc actccctcat accattctc aaattgtgac 5040
tgagtggcac gagtgtaga aatgtcaatt tgttgcggat tatactgaag aagatgattt 5100
aaattaagga cagtctttcc cttaattctc ggtagaaatc atcgatcca tggtagcac 5160
tgcagatcgt tcaaacattt ggcaataaag tttcttaaga ttgaatcctg ttgccggtct 5220
tgcgatgatt atcatataat ttctgttgaa ttacgttaag catgtaataa ttaacatgta 5280
atgcatgacg ttatttatga gatgggtttt tatgattaga gtcccgcaat tatacattta 5340
atacgcgata gaaaacaaaa tatagcgcgc aaactaggat aaattatcg gcgcggtgtc 5400
atctatgtta ctgatctct agaaagcttc gtacgttaat taattcgaat ccggagcggc 5460
cgcagggtta tactcacggy tgcgatgcc ccatcgtag gtgaagggtg aaattaatga 5580
tccatcttga gaccacaggy ccacaacagc taccagtttc ctcaagggtc caccaaaaac 5640
gtaagcgctt acgtacatgg tcgataagaa aaggcaattt gtagatgtta acatccaacg 5700
tcgctttcag ggtaccgaa ttccaagctt ggaattcggg atctacagg ccaaattcgc 5760
tcttagccgt acaatattac tcaccggtgc gatgcccccc atcgtagggtg aaggtggaaa 5820
ttaatgatcc atcttgagac cacaggccca caacagctac cagtttctc aaggtccac 5880
caaaaacgta agcgttacg tacatggtcg ataagaaaag gcaatttgta gatgttaaca 5940
tccaacgtcg ctttcaggga tcccgaaatc caagcttggg attcggggtc ctacaggcca 6000
aattcgctct tagcgtaca atattactca ccggtgcgat ccccccacg taggtgaagg 6060
tggaaattaa tgatccatct tgagaccaca ggccacaac agctaccagt ttctcaagg 6120
gtccacaaaa aacgtaagcg cttacgtaca tggctgataa gaaaaggcaa tttgtagatg 6180
ttaacatcca acgtcgcttt cagggatccc gaattccaag cttgggctgc aggtcaatcc 6240

```

cattgctttt	gaagcagctc	aacattgatc	tctttctcga	gggagatttt	tcaaatcagt	6300
gcgcaagacg	tgacgtaagt	atccgagtc	gtttttat	ttctactaat	ttgggtcg	6360
atttcggcgt	gtaggacatg	gcaaccgggc	ctgaatttcg	cgggtattct	gtttctattc	6420
caactttt	ttgatccgca	gccattaacg	acttttgaat	agatacgtg	acacgccaa	6480
cctcgctagt	caaaagtgt	caaacaacg	ctttacagca	agaacggaat	gcgcgtgacg	6540
ctcgcggtga	cgccatttcg	ccttttcaga	aatggataaa	tagccttgct	tcctattata	6600
tcttcccaaa	ttaccaatac	attacactag	catctgaatt	tcataacca	tctcgataca	6660
caaactcgag	atctgcaggg	atccccgatc	atgcaaaaac	tcattaactc	agtgcaaaac	6720
tatgcctggg	gcagcaaaac	ggcgttgact	gaactttatg	gtatggaaaa	tccgtccagc	6780
cagccgatgg	ccgagctgtg	gatgggagca	catccgaaaa	gcagttcacg	agtgcagaat	6840
gcccgcggag	atatcgtttc	actgcgtgat	gtgattgaga	gtgataaatc	gactctgctc	6900
ggagaggccg	ttgccaaaacg	ctttggcgaa	ctgcctttcc	tgttcaaagt	attatgcgca	6960
gcacagccac	tctccattca	ggttcattca	aacaaacaca	attctgaaat	cggttttg	7020
aaagaaaatg	ccgcaggtat	ccgatggat	gcgcgcgagc	gtaactataa	agatccctaac	7080
cacaagccgg	agctggtttt	tgcgctgacg	cctttccttg	cgatgaacgc	gtttcgtgaa	7140
ttttccgaga	ttgtctccct	actccagccg	gtcgaggtg	cacatccggc	gattgctcac	7200
tttttacaac	agcctgatgc	cgaacgttta	agcgaactgt	tcgccagcct	gttgaaatag	7260
cagggtgaag	aaaaatcccg	cgcgctggcg	attttaaaat	cggccctcga	tagccagcag	7320
ggtgaaccgt	ggcaaacgat	tcgtttaatt	tctgaatttt	acccggaaga	cagcggctctg	7380
ttctccccgc	tattgctgaa	tgtggtgaaa	ttgaaccctg	gcgaagcgat	gttcctgttc	7440
gctgaaacac	cgcacgctta	cctgcaaggc	gtggcgctgg	aagtgatggc	aaactccgat	7500
aacgtgctgc	gtgcgggtct	gacgcctaaa	tacattgata	ttccggaact	ggttgccaat	7560
gtgaaattcg	aagccaaacc	ggtaaccag	ttgttgaccc	agccggtgaa	acaaggtgca	7620
gaactggact	tcccgattcc	agtggatgat	tttgcttct	cgctgcatga	ccttagtgat	7680
aaagaaacca	ccattagcca	gcagagtgcc	gccattttgt	tctgcgtcga	aggcgatgca	7740
acgttgtgga	aaggttctca	gcagttacag	cttaaaccgg	gtgaatcagc	gtttattg	7800
gccaacgaat	caccggtgac	tgtcaaaggc	cacggccgtt	tagcgcgtgt	ttacaacaag	7860
ctgtaagagc	ttactgaaa	aattaacatc	tcttgctaag	ctgggagctc	gtcgacggat	7920
cgaattcctg	cagatcgctc	aaacatttgg	caataaagtt	tcttaagatt	gaatcctgtt	7980
gcccgtcttg	cgatgattat	catataattt	ctgttgaaat	acgttaagca	tgtaataatt	8040
aacatgtaat	gcatgacgtt	atttatgaga	tgggttttta	tgattagagt	cccgcaatta	8100
tacatttaat	acgcgataga	aaacaaaata	tagcgcgcaa	actaggataa	attatcgcgc	8160
gcgggtgcat	ctatgttact	agatctctag	aactagtgga	tctgctagcc	ctgcaggaaa	8220
tttacogggt	cccgggcggc	cagcatggcc	gtatccgcaa	tgtgttatta	agttgtctaa	8280
gcgtcaattt	gtttacacca	caatatatcc	tgccaccagc	cagccaacag	ctccccgacc	8340
ggcagctcgg	cacaaaatca	ccactcgata	caggcagccc	atcagaatta	attctcatgt	8400
ttgacagctt	atcatcgact	gcacggtgca	ccaatgcttc	tggcgtcagg	cagccatcgg	8460
aagctctggt	atggctgtgc	aggtcgtaaa	tcactgcata	attcgtgtcg	ctcaaggcgc	8520
actcccgctt	tggataatgt	tttttgcgcc	gcacatcata	cggttctggc	aaatattctg	8580
aatgagctg	ttgacaatta	atcatcggct	cgtataatgt	gtggaattgt	gagcggataa	8640
caatttcaca	caggaaacag	accatgaggg	aagcgggtgat	cgccgaagta	tcgactcaac	8700
tatcagaggt	agttggcgtc	atcgagcgcc	atctcgaacc	gacgttgctg	gccgtacatt	8760
tgtacggctc	cgcagtggtg	ggcggcctga	agccacacag	tgatattgat	ttgctgggta	8820
cggtgaccgt	aaggcttgat	gaaacaacgc	ggcgagcttt	gatcaacgac	cttttgga	8880
cttcggcttc	ccctggagag	agcgagattc	tccgcgctgt	agaagtcacc	attggtgtgc	8940
acgacgacat	cattccgtgg	cgttatccag	ctaagcgcca	actgcaattt	ggagaatggc	9000
agcgcaatga	cattcttgca	ggtatcttcg	agccagccac	gatcgacatt	gatctggcta	9060
tcttgctgac	aaaagcaaga	gaacatagcg	ttgccttggg	aggtccagcg	gcggaggaa	9120
tctttgatcc	ggttcctgaa	caggatctat	ttgaggcgct	aaatgaaacc	ttaacgctat	9180
ggaactcgcc	gcccgactgg	gctggcgatg	agcgaaatgt	agtgcttacg	ttgtcccga	9240
tttggtacag	cgcagtaacc	ggcaaaatcg	cgccgaagga	tgtcgctgcc	gactgggcaa	9300
tggagcgctt	gcccggccag	tatcagcccg	tcatacttga	agctaggcag	gcttatcttg	9360
gacaagaaga	tcgcttgccc	tcgycgcgag	atcagttgga	agaatttggt	cactacgtga	9420
aaggcgagat	caccaaggta	gtcggcaaat	aaagctctag	tggatccccg	aggaatcggc	9480
gtgacggctg	caaaccatcc	ggcccggtac	aaatcggcgc	ggcgctgggt	gatgacctgg	9540
tggagaagtt	gaaggccgcg	caggccgccc	agcggcaacg	catcgaggca	gaagcacgcc	9600

```

ccggtgaatc gtggcaagcg gccgctgac gaatccgcaa agaatcccg caaccccg 9660
cagccggtgc gccgtcgatt aggaagccgc ccaagggcga cgagcaacca gattttttcg 9720
ttccgatgct ctatgacgtg ggcaccccg atagtcgcag catcatggac gtggccgttt 9780
tccgtctgtc gaagcgtgac cgacgagctg gcgaggtgat ccgctacgag cttccagacg 9840
ggcacgtaga ggtttcagca gggccggccg gcattggccag tgtgtgggat tacgacctgg 9900
tactgatggc ggtttcccat ctaaccgaat ccatgaaccg ataccgggaa gggaaaggag 9960
acaagcccg cgcgctgttc cgtccacacg ttgcggacgt actcaagttc tgccggcgag 10020
ccgatggcgg aaagcagaaa gacgacctgg tagaaacctg cattcggtta aacaccacgc 10080
acgttgccat gcagcgtacg aagaaggcca agaagggccg cctggtgacg gtatccgagg 10140
gtgaagcctt gattagcgcg tacaagatcg taaagagcga aaccgggagg ccggagtaca 10200
tcgagatcga gctagctgat tggatgtacc gcgagatcac agaaggcaag aaccgggacg 10260
tgctgacggg tcaccccgat tactttttga tcgatcccg catcgccgtt tttctctacc 10320
gcctggcagc ccgcccgcga ggcaaggcag aagccagatg gttgttcaag acgatctacg 10380
aacgcagtgg cagcgcggga gagttcaaga agttctgttt caccgtgcgc aagctgatcg 10440
ggtcaaataa cctgcccggg tacgatttga aggaggaggc ggggcaggct ggcccgatcc 10500
tagtcatgcg ctaccgcaac ctgatcgagg gcgaagcatc cgccggttcc taatgtacgg 10560
agcagatgct agggcaaat gccctagcag gggaaaaagg tcgaaaagg ctctttctcg 10620
tggatagcac gtacattggg aacccaaagc cgtacattgg gaaccgggaa ccgtacattg 10680
ggaacccaaa gccgtacatt ggggaaccgg cacacatgta agtgactgat ataaaagaga 10740
aaaaaggcga tttttccgcc taaaactctt taaaactctt aaaaccggcc 10800
tggcctgtgc ataactgtct ggccagcgca cagccgaaga gctgcaaaaa ggccttacc 10860
ttcggctgct gcgtcccta cgcgcccg cttcgcgtcg gcctatcgcg gccgctggcc 10920
gctcaaaaat ggctggccta cggccaggca atctaccagg gcgaggacaa gccgcgccgt 10980
cgccactcga ccgcccggcg tgaggtctgc ctctgaaga aggtgttgct gactcatacc 11040
aggcctgaat cgcgccatca tccagccaga aagtggagg gccacgggtg atgagagctt 11100
tgtttaggtt ggaccagttg gtgattttga acttttgctt tgccacggaa cggctctgct 11160
tgtcgggaag atgcgtgatc tgatccttca actcagcaaa agttcgattt attcaaaaa 11220
gccgcccgtc cgtcaagtca gcgtaatgct ctgccagtgt tacaaccaat taaccaatc 11280
tgattagaaa aactcatcga gcatcaaatg aaactgcaat ttattcatat caggattatc 11340
aataccatat ttttgaaaaa gccgtttctg taatgaagga gaaaactcac cgaggcagtt 11400
ccataggatg gcaagatcct ggtatcggtc tgcgattccg actcgtccaa catcaataca 11460
acctattaat ttcccctcgt caaaaataag gttatcaagt gagaaatcac catgagtac 11520
gactgaatcc ggtgagaatg gcaaaagctc tgcattaatg aatcgcccaa ccgcccggga 11580
gaggcggttt gcgtattggg cgtctcttcg cttcctcgct cactgactcg ctgcgctcgg 11640
tcgttcggct gcgcccagcg gtatcagctc actcaaaggc ggtaatacgg ttatccacag 11700
aatcagggga taacgcagga aagaacatgt gagcaaaagg ccagcaaaag gccagggaacc 11760
gtaaaaaggc cgcgttgctg gcgtttttcc ataggctccg ccccccgtgac gagcatcaca 11820
aaaatcgacg ctcaagtcag aggtggcgaa acccgacagg actataaaga taccaggcgt 11880
ttcccctggg aagtcctcgc gtgcgtctc ctgttcggac cctgcccgtt accggatacc 11940
tgtccgcctt tctccctcgc ggaagcgtg cgctttctca atgctcacgc tgtaggtatc 12000
tcagttcggg gtaggtcggt cgtcccaagc tgggctgtgt gcacgaaccc cccgttcagc 12060
ccgaccgctg cgccttatcc ggttaactat gtcttgagtc caaccgggta agacacgact 12120
tatcgccact ggcagcagcc actggtaaca ggattagcag agcgagggtat gtaggcgggtg 12180
ctacagagtt cttgaagtgg tggcctaact acggctacac tagaaggaca gtatttggtg 12240
tctgcgctct gctgaagcca gttacctcgc gaaaaagagt tggtagctct tgatccggca 12300
aacaaccac cgcgtgtagc ggtgggtttt ttgtttgcaa gcagcagatt acgcgcagaa 12360
aaaaaggatc tcaagaagat cctttgatct tttctacggg gtctgacgct cagtggaaag 12420
aaaactcacg ttaagggtat ttggtcatga gattatcaaa aaggatcttc acctagatcc 12480
ttttgatccg gaattaatc ctgtggttgg ctgtcacata caaatggagc aacggataaa 12540
ccttttcacg cctttttaa tatcgatta ttctaataaa cgctcttttc tcttaggttt 12600
accgccaat atatctgtc aaacactgat agtttaact gaaggcgga aacgacaatc 12660
tgatcatgag cggagaatta agggagtcac gttatgacct ccgcccagta ccggggacaa 12720
gccgttttac gtttggaaact gacagaaccg caacgctgca ggaatt 12766

```

<211> 42
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: ZUP1598

<400> 26
catgccatgg atccaatggc cacgaattaa agctatcacg tc

42

<210> 27
<211> 44
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: ZUP1590

<400> 27
acgcgtcgac cgcggattca aacgattatt aattacgata aaag

44

<210> 28
<211> 11461
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: pZU634

<220>
<221> promoter
<222> (55)..(1786)
<223> ubiquitin3 promoter plus leader intron

<220>
<221> misc_feature
<222> (1790)..(2574)
<223> PVY nt CP region

<220>
<221> intron
<222> (2595)..(3036)
<223> actin2 intronL

<220>
<221> misc_feature
<222> Complement((3057)..(3847))
<223> PVY nt CP region

<220>
<221> terminator
<222> (3855)..(4124)
<223> NOS terminator

```

<220>
<221> promoter
<222> (4193)..(5364)
<223> SMAS promoter

<220>
<221> gene
<222> (5386)..(6561)
<223> phosphomannose isomerase A coding sequence

<220>
<221> terminator
<222> (6623)..(6897)
<223> nopaline synthase terminator

<220>
<221> misc_feature
<222> (6949)..(7080)
<223> nopaline left border fragment

<220>
<221> gene
<222> (7359)..(8147)
<223> spectinomycin (aadA) coding sequence

<220>
<221> misc_structure
<222> (8157)..(10244)
<223> pVS1 ORI

<220>
<221> misc_structure
<222> (10245)..(11179)
<223> pUC19 ORI

<220>
<221> misc_feature
<222> (11195)..(11450)
<223> nopaline right border region

<220>
<221> stem_loop
<222> (1790)..(3847)
<223> PVY inverted repeat region

<400> 28
ggcgcgagcg gccatttaaa tcaattgggc gcgcgaatt cgagctcggt acccgtagcg 60
gatttggagc caagtctcat aaacgccatt gtggaagaaa gtcttgagtt ggtggtaatg 120
taacagagta gtaagaacag agaagagaga gagtgtgaga tacatgaatt gtcgggcaac 180
aaaaatcctg aacatcttat tttagcaaag agaaagagtt ccgagtctgt agcagaagag 240
tgaggagaaa ttttagctct tggacttgtg aattgttcog cctcttgaat acttcttcaa 300
tcctcatata ttcttcttct atgttacctg aaaaccggca tttaatctcg cgggtttatt 360
ccggttcaac attttttttg ttttgagtta ttatctgggc ttaataacgc aggcctgaaa 420
taaattcaag gcccaactgt tttttttttt aagaagttgc tgtaaaaaaa aaaaaaaggg 480
aattaacaac aacaacaaaa aaagataaag aaaataataa caattacttt aattgtagac 540
taaaaaaaca tagattttat catgaaaaaa agagaaaaa aataaaaaact tggatcaaaa 600

```

aaaaaaacat	acagatcttc	taattattaa	cttttcttaa	aaattaggtc	ctttttccca	660
acaattaggt	ttagagtttt	ggaattaaac	caaaaagatt	gttctaaaaa	atactcaa	720
ttggtagata	agtttcctta	ttttaattag	tcaatggtag	atactttttt	ttcttttctt	780
tattagagta	gattagaatc	ttttatgcca	agttttgata	aattaaatca	agaagataaa	840
ctatcataat	caacatgaaa	ttaaaagaaa	aatctcatat	atagtattag	tattctctat	900
atatattatg	attgcttatt	cttaatgggt	tgggttaacc	aagacatagt	cttaatggaa	960
agaatctttt	ttgaactttt	tccttattga	ttaaattctt	ctatagaaaa	gaaagaaatt	1020
at ttgaggaa	aagtatatac	aaaaagaaaa	atagaaaaat	gtcagtgaag	cagatgta	1080
ggatgaccta	atccaaccac	caccatagga	tgtttctact	tgagtgggtc	ttttaaaaa	1140
gcacgggtgga	aaatattgaca	cgtatcatat	gattccttcc	tttagtttcg	tgataataa	1200
cctcaactga	tatcttcctt	tttttgtttt	ggctaaagat	at tttattct	cattaataga	1260
aaagacgggt	ttgggctttt	ggtttgcgat	ataaagaaga	ccttcgtgtg	gaagataata	1320
attcatcctt	tcgtcttttt	ctgactcttc	aatctctccc	aaagcctaaa	gcgatctctg	1380
caaattctctc	gcgactctct	ctttcaaggt	atattttctg	attctttttg	tttttgatc	1440
gtatctgac	tccaattttt	gttatgtgga	ttattgaatc	ttttgtataa	attgcttttg	1500
acaatattgt	tcgtttcgtc	aatccagctt	ctaaattttg	tcctgattac	taagatatcg	1560
attcgtagtg	tttacatctg	tgtaatttct	tgcttgattg	tgaaattagg	at tttcaagg	1620
acgatctatt	caatttttgt	gttttctttg	ttcgattctc	tctgttttag	gtttcttatg	1680
tttagatccg	tttctctttg	gtgttgtttt	gatttctctt	acggcttttg	at ttgggtata	1740
tggtcgctga	ttggtttcta	ctgttcttat	tgttttattt	caggtggggg	atccaattggc	1800
cacgaattaa	agctatcacg	tccaaaatga	gaatgcccaa	gagtaagggt	gcaactgtac	1860
taaatttgga	acacctactc	gagtatgctc	cacagcaaat	tgaaatctca	aatactcgag	1920
caactcaatc	acagtttgat	acatgggatg	aagcagtaca	acttgcatac	gacataggag	1980
aaactgaaat	gccaaactgtg	atgaatgggc	ttatggtttg	gtgcattgaa	aatggaacct	2040
cgccaaatat	caatggagtt	tgggttatga	tggatggaga	tgaacaagtc	gaatacccac	2100
tgaaccaaat	cgttgagaat	gcaaaaacca	cacttaggca	aatcatggca	catttctcag	2160
atgttgacaga	agcgtatata	gaaatgcgca	acaaaaagga	accatatatg	ccacgatatg	2220
gtttagtctg	taactctg	gatggaagtt	tggtctgcta	tgcttttgac	ttttatgaag	2280
ttacatcacg	tacaccagtg	agggctagag	aggcacacat	tcaaatgaag	gccgcagctt	2340
taaaatcagc	tcaatctcga	cttttcggat	tggatgggtg	cattagtaca	caagaggaaa	2400
acacagagag	gcacaccacc	gaggatgttt	ctccaagtat	gcatactcta	cttggagtga	2460
agaacatgtg	attgtagtgt	ctttccggac	gatataataga	tatttatgtt	tgacagta	2520
at tttggctt	ttctctgact	acttttatcg	taattaataa	tcgtttgaat	ccgcccgcgc	2580
tctttctttc	caaggtaata	ggaactttct	ggatctactt	tatttgctgg	atctcgatct	2640
tgttttctca	at ttccttga	gatctggaat	tcgtttaatt	tggatctgtg	aacctccact	2700
aaatcttttg	gttttactag	aatcgatcta	agttgaccga	tcagttagct	cgattatagc	2760
taccagaatt	tggttgacc	ttgatggaga	gatccatgtt	catgttacct	gggaaatgat	2820
ttgtatatgt	gaattgaaat	ctgaactgtt	gaagttagat	tgaatctgaa	cactgtcaat	2880
gttagattga	atctgaacac	tgtttaagtt	agatgaagtt	tgtgtataga	ttcttcgaaa	2940
ctttaggatt	tgtagtgtcg	tacgttgaac	agaaagctat	ttctgattca	atcagggttt	3000
at ttgactgt	attgaactct	ttttgtgtgt	ttgcagctca	taaaaaatgg	cgtcgaccgc	3060
ggattcaaac	gattattaat	tacgataaaa	gtagtacagg	aaaagccaaa	atacttactg	3120
caaacataaa	tatctatata	tcgtccggaa	agacactaca	atcacatgtt	cttcactcca	3180
agtagagtat	gcatacttgg	agaaacatcc	tcggtggtgt	gcctctctgt	gttttctctt	3240
tgtgtactaa	tgccaccatc	caatccgaaa	agtcgagatt	gagctgattt	taaagctgcg	3300
gccttcattt	gaatgtgtgc	ctctctagcc	ctcactgggtg	tacgtgatgt	aacttcataa	3360
aagtcaaaag	catagcgagc	caaacttcca	tcgcgcagat	tacgaactaa	accatatcgt	3420
ggcatatatg	gttccttttt	gttgcgcat	tctatatacg	cttctgcaac	atctgagaaa	3480
tgtgccatga	tttgccctaag	tgttgggttt	gcatttctcaa	cgattgggtt	cagtgggtat	3540
tcgacttggt	catctccatc	catcataacc	caaactccat	tgatatttgg	cgagggtcca	3600
ttttcaatgc	accaaaccat	aagcccattc	atcacagttg	gcatttcagt	ttctcctatg	3660
tcgtatgcaa	gttgactgc	ttcataccat	gtatcaaact	gtgattgagt	tgctcgagta	3720
tttgagattt	caatttgctg	tggagcatat	tcgagtaggt	gttccaaatt	tagtacagtt	3780
gcacccttac	tcttgggcat	tctcatattg	gacgtgatag	ctttaattcg	tggccattgg	3840
atccatggtg	atcactgcag	atcggttcaa	catttggtgaa	taaagtttct	taagattgaa	3900
tcctgttgcc	ggtcttgoga	tgattatcat	ataatttctg	ttgaattacg	ttaagcatgt	3960

aataattaac atgtaatgca tgacgttatt tatgagatgg gtttttatga ttagagtccc 4020
gcaattatac atttaatacg cgatagaaaa caaaatatag cgcgcaacct aggataaatt 4080
atcgcgcgcg gtgtcatcta tgttactaga tctctagaaa gcttcgtacg ttaattaatt 4140
cgaatccgga gcggccgcag ggctagcatc gatggtagcg agctcgagac tatacaggcc 4200
aaattcgctc ttagccgtac aatattactc accggtgcga tgccccccat cgtagggtgaa 4260
gggtgaaatt aatgatccat cttgagacca caggcccaca acagctacca gtttcctcaa 4320
gggtccacca aaaacgtaag cgcttacgta catggctgat aagaaaaggc aatttgtaga 4380
tgtaacatc caacgtcgct ttcagggatc ccgaattcca agcttggaat tggggatcct 4440
acaggccaaa ttcgctctta gccgtacaat attactcacc ggtgcgatgc ccccatcgt 4500
agggtgaagg ggaaattaat gatccatctt gagaccacag gccacaaca gctaccagtt 4560
tcctcaaggg tccaccaaaa acgtaagcgc ttacgtacat ggtcgataag aaaaggcaat 4620
ttgtagatgt taacatccaa cgctcgctttc agggatcccg aattccaagc ttggaattcg 4680
ggatccctaca ggccaaattc gctcttagcc gtacaatatt actcaccggg gcgatcccc 4740
catcgtaggt gaagggtgaa attaatgatc catcttgaga ccacaggccc acaacagcta 4800
ccagtttctt caagggtcca ccaaaaacgt aagcgcttac gtacatgggc gataagaaaa 4860
ggcaatttgt agatgttaac atccaacgtc gctttcaggg atcccgatc ccaagcttgg 4920
gctgcaggtc aatcccattg cttttgaagc agctcaacat tgatctcttt ctcgaggagg 4980
atttttcaaa tcagtgcgca agacgtgacg taagtatccg agtcagtttt tatttttcta 5040
ctaatttggt cgtttatttc ggcggtgtagg acatggcaac cgggcctgaa tttcgcggtt 5100
attctgtttt ttctcaact tttcttgat ccgcagccat taacgacttt tgaatagata 5160
cgctgacacg ccaagcctcg ctagtcaaaa gtgtacaaa caacgcttta cagcaagaac 5220
ggaatgcgcg tgacgctcgc ggtgacgcca tttcgcttt tcagaaatgg ataaatagcc 5280
ttgcttctta ttatatcttc ccaattacc aatacattac actagcatct gaatttcata 5340
accaatctcg atacacaaaa tcgagatctg cagggatccc cgatcatgca aaaactcatt 5400
aactcagtcg aaaactatgc ctggggcagc aaaacggcgt tgactgaact ttatggtag 5460
gaaaaatcgt ccagccagcc gatggccgag ctgtggatgg gcgcacatcc gaaaagcagt 5520
tcacgagtgc agaatgccgc cggagatcgc gtttactgct gtgatgtgat tgagagtgat 5580
aaatcgactc tgctcggaga ggccgttgcc aaacgctttg gcgaactgcc tttcctgttc 5640
aaagtattat gcgcagcaca gccactctcc attcaggttc atccaaaca acacaattct 5700
gaaatcgggt ttgccaaaaga aaatgccgca ggtatccga tggatgccgc cgagcgtaac 5760
tataaagatc ctaaccacaa gccggagctg gtttttgcc tgacgccttt ccttgcgatg 5820
aacgcgtttc gtgaattttc cgagattgtc tccctactcc agccggtcgc aggtgcacat 5880
cggcgatttg ctacttttt acaacagcct gatgccgaac gtttaagcga actgttcgcc 5940
agcctgttga atatgcaggg tgaagaaaaa tcccgccgc tggcgatttt aaaatcggcc 6000
ctcgatagcc agcaggggtga accgtggcaa acgattcgtt taatttctga atttaccog 6060
gaagacagcg gtcgtttctc cccgctattg ctgaatgtgg tgaaattgaa ccctggcgaa 6120
gcgatgttcc tgctcgtgta aacaccgcac gcttacctgc aaggcgtggc gctggaagt 6180
atggcaactc cgataacgt gctgcgtgcg ggtctgacgc ctataacat tgatattccg 6240
gaactggttg ccaatgtgaa attogaagc aaaccggcta accagttgtt gaccagcog 6300
gtgaaacaag gtgcagaact ggacttccc attccagtgg atgattttgc cttctcgctg 6360
catgacctta gtgataaaga aaccaccatt agccagcaga gtgccgccat tttgttctgc 6420
gtogaaggcg atgcaacgtt gtggaaagg tctcagcagt tacagcttaa accgggtgaa 6480
tcagcgttta ttgccccaa cgaatcaccg gtgactgtca aaggccacgg ccgttttagc 6540
cgtgtttaca acaagctgta agagcttact gaaaaaatta acatctcttg ctaagctggg 6600
agctcgtcga cggatcgaat tcttcgagat cgttcaaaca tttggcaata aagtttctta 6660
agattgaatc ctggtgccgg tcttcgagat attatcatat aatttctgtt gaattacgtt 6720
aagcatgtaa taattaacat gtaatgcatg acgttattta tgagatgggt ttttatgatt 6780
agagtccgc aattatacat ttaatacgcg atagaaaaa aaatatagcg cgcaactag 6840
gataaattat cgcgcgcggg gtcatctatg ttactagatc tctagaacta gtggatctgc 6900
tagccctgca ggaaatttac cgtgcccgc gggccagca tggccgtatc cgcaatgtgt 6960
tattaagttg tctaagcgtc aatttgttta caccacaata tatcctgcca ccagccagcc 7020
aacagctccc cgaccggcag ctccgcacaa aatcaccact cgatacaggc agcccatcag 7080
aattaattct catgtttgac agcttatcat cgactgcacg gtgcaccaat gcttctggcg 7140
tcaggcagcc atcggaagct gtggtatggc tgtgcaggtc gtaaatcact gcataattcg 7200
tgtcgctcaa ggcgcactcc cgttctggat aatgttttt gcgcggacat cataacggtt 7260
ctggcaataa ttctgaaatg agctgttgac aattaatcat cggctcgtat aatgtgtgga 7320

attgtgagcg gataacaatt tcacacagga aacagaccat gagggagcg gtgatcgccg 7380
 aagtatcgac tcaactatca gaggtagttg gcgtcatcga gcgccatctc gaaccgacgt 7440
 tgctggccgt acatttgtag ggctccgcag tggatggcgg cctgaagcca cacagtata 7500
 ttgatttgct gggtacggtg accgtaaggc ttgatgaaac aacgcggcga gctttgatca 7560
 acgacctttt ggaaacttcg gcttccctcg gagagagcga gattctccgc gctgtagaag 7620
 tcaccattgt tgtgcacgac gacatcatc cgtggcggtta tccagctaag cgcgaactgc 7680
 aatttgagga atggcagcgc aatgacattc ttgcaggtat cttcgagcca gccacgatcg 7740
 acattgatct ggctatcttg ctgacaaaag caagagaaca tagcgttgcc ttggtaggtc 7800
 cagcggcgga ggaactcttt gatccggttc ctgaacagga tctatttgag gcgctaaatg 7860
 aaaccttaac gctatggaac tcgcgcgcg actgggctgg cgatgagcga aatgtagtgc 7920
 ttacgttgct ccgcatttggt tacagcgag taaccggcaa aatcgcgccg aaggatgtcg 7980
 ctgcccactg ggcaatggag cgcctgccg cccagtatca gcccgtcata cttgaagcta 8040
 ggcaggtcta tcttggaaca gaagatcgct tggcctcgcg cgcagatcag ttggaagaat 8100
 ttgttacta cgtgaaaggc gagatcacca aggtagtcgg caaataaagc tctagtggat 8160
 ccccgaggaa tcggcggtgac ggtcgcaaac catccggccc ggtacaaatc ggcgcgcg 8220
 tgggtgatga cctggtggag aagttgaagg ccgcgcagcg cgcgcagcg caacgcacatc 8280
 aggagaagc acgccccggt gaatcgtggc aagcggccgc tgatcgaatc cgcaagaat 8340
 cccggcaacc gccggcagcc ggtgcgcgt cgattaggaa gccgccaag gccgacgagc 8400
 aaccagatct ttctgttcg atgctctatg acgtgggac ccgcgatagt cgcagatca 8460
 tggacgtggc cgttttccgt ctgtcgaagc gtgaccgag agctggcgag gtgatccgt 8520
 acgagcttcc agacgggac gtagaggttt cagcagggcc ggccggcatg gccagtgtgt 8580
 gggattacga cctggtactg atggcggttt cccatctaac cgaatccatg aaccgatacc 8640
 ggggaagggaa gggagacaag cccggccgcg tgttccgtcc acacgttgcg gacgtactca 8700
 agttctgccc gcgagccgat ggcggaagc agaaagacga cctggtagaa acctgcattc 8760
 ggttaaacac cagcacggt gccatgcagc gtacgaagaa ggccaagaac ggccgcctgg 8820
 tgacggtatc cgagggtgaa gccttgatta gccgctacaa gatcgtaaag agcgaaccg 8880
 ggcggccgga gtacatcgag atcgagctag ctgattggat gtaccgcgag atcacagaag 8940
 gcaagaaccc ggacgtgctg acggttcacc ccgattactt tttgatcgat cccggcatcg 9000
 gccgttttct ctaccgcctg gcacgcgcg ccgcaggcaa ggcagaagcc agatggttgt 9060
 tcaagacgat ctacgaacgc agtggcagcg ccggagagtt caagaagttc tgtttcacg 9120
 tgcgcaagct gatcgggtca aatgacctgc cggagtacga tttgaaggag gaggcggggc 9180
 aggctggccc gatcctagtc atgcgctacc gcaacctgat cgaggcgcaa gcatccgccc 9240
 gttcctaatag tacggagcag atgctagggc aaattgccct agcaggggaa aaaggctcga 9300
 aaggtctctt tcctgtggat agcacgtaca ttgggaaccc aaagccgtac attgggaacc 9360
 ggaacccgta cattgggaac ccaaagccgt acattgggaa ccggtcacac atgtaagtga 9420
 ctgatataaa agagaaaaaa ggcgattttt ccgcctaaaa ctctttaaaa cttattaaaa 9480
 ctcttaaaac ccgcctggcc tgtgcataac tgtctggcca gcgcacagcc gaagagctgc 9540
 aaaaagcgcc tacccttcg tcgctgcgt ccctacgccc cgcgcttcg cgtcggccta 9600
 tcgcggccgc tggccgctca aaaatggctg gcctacggcg aggcaatcta ccaggcgcg 9660
 gacaagcgc gccgtcgcca ctgcagccgc ggcgctgagg tctgcctcgt gaagaagtg 9720
 ttgctgactc ataccaggcc tgaatcgccc catcatccag ccagaaagtg agggagccac 9780
 ggttgatgag agctttgttg taggtggacc agttggtgat tttgaacttt tgctttgcca 9840
 cggaacggtc tgcgtgtgog ggaagatgog tgatctgac cttcaactca gcaaaagtcc 9900
 gatttattca acaaagccgc cgtcccgtca agtcagcgta atgctctgcc agtgttataa 9960
 ccaattaacc aattctgatt agaaaaactc atcgagcatc aaatgaaact gcaatttatt 10020
 catatcagga ttatcaatac catatttttg aaaaagccgt tctgtaatg aaggagaaaa 10080
 ctccagagc agttccata ggatggcaag atcctggtat cggctctgca ttccgactcg 10140
 tccaacatca atacaaccta ttaatttccc ctogtcaaaa ataaggttat caagttagaa 10200
 atcaccatga gtgacgactg aatccggtga gaatggcaaa agctctgcat taatgaatcg 10260
 gccaacgccc ggggagaggc ggtttgcgta ttggcgctc ttccgcttc tcgctcactg 10320
 actcgtgog ctccgctggt cggctgccc gagcggatc agctcactca aaggcggtaa 10380
 tacggttatc cacagaatca ggggataacg caggaaagaa catgtgagca aaaggccagc 10440
 aaaaggccag gaaccgtaaa aaggccgcgt tgcgtggcgt tttccatagg ctccgcccc 10500
 ctgacgagca tcacaaaaat cgacgctcaa gtcagaggtg gcgaaccccg acaggactat 10560
 aaagatacca ggcgtttccc cctggaagct ccctcgtgog ctctcctgtt ccgacctgc 10620
 cgcttaccgg atacctgtcc gcctttctcc cttcggaag cgtggcgctt tctcaatgct 10680

cacgctgtag gtatctcagt tcggtgtagg tcgttcgctc caagctgggc tgtgtgcacg 10740
aacccccgt tcagcccgac cgctgcgcct tatccggtaa ctatcgtctt gagtccaacc 10800
cggtaagaca cgacttatcg ccactggcag cagccactgg taacaggatt agcagagcga 10860
ggtatgtagg cgggtgctaca gagttcttga agtgggtggc taactacggc tacactagaa 10920
ggacagtatt tggatatctgc gctctgctga agccagttac cttcggaaaa agagttggta 10980
gctcttgatc cggcaaaaa accacgctg gtagcgggtg tttttttgtt tgcaagcagc 11040
agattacgcg cagaaaaaaa ggatctcaag aagatccttt gatcttttct acggggtctg 11100
acgctcagtg gaacgaaaac tcacgttaag ggatttttgt catgagatta tcaaaaagga 11160
tcttcaccta gatccttttg atccggaatt aattcctgtg gttggcatgc acatacaaat 11220
ggacgaacgg ataaaccttt tcacgccctt ttaaataatcc gattattcta ataaacgctc 11280
ttttctctta gggtttaccg ccaatatatc ctgtcaaaca ctgatagttt aaactgaagg 11340
cgggaaacga caatctgatc atgagcggag aattaaggga gtcacgttat gacccccgcc 11400
gatgacgcgg gacaagccgt ttacgtttg gaactgacag aaccgcaacg ctgcaggaat 11460
t 11461

PCF/EP 00/04117

IPC 7 C12N15/11 C12N15/63 C12N15/82 A01N63/00 A01H5/00

According to International Patent Classification (IPC) or to both national classification and IPC

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12N A01N A01H

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, BIOSIS, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>WATERHOUSE ET AL: "Virus resistance and gene silencing in plants can be induced by simultaneous expression of sense and antisense RNA"</p> <p>PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, US, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, vol. 95, no. 95, November 1998 (1998-11), pages 13959-13964, XP002114472 ISSN: 0027-8424</p>	<p>1-7, 23, 27, 28, 30-33</p>
Y	<p>the whole document</p> <p style="text-align: center;">— -/-</p>	<p>10-13</p>

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T"** later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X"** document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y"** document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- "A"** document member of the same patent family

Date of the actual completion of the international search

4 September 2000

Date of mailing of the international search report

21/09/2000

Name and mailing address of the ISA
European Patent Office, P.B. 5818 Patentaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 851 epo nl,
Fax (+31-70) 340-3018

Authorized officer

Maddox, A

INTERNATIONAL SEARCH REPORT

International Application No

PC1/EP 00/04117

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	SIJEN TITIA ET AL: "RNA-mediated virus resistance: Role of repeated transgenes and delineation of targeted regions." PLANT CELL, vol. 8, no. 12, 1996, pages 2277-2294, XP002146482 ISSN: 1040-4651	1-6, 10-13, 27,30-33
Y	page 2284, left-hand column	10-13
P,X	WO 99 53050 A (WANG MING BO ;COMMW SCIENT IND RES ORG (AU); GRAHAM MICHAEL WAYNE) 21 October 1999 (1999-10-21) the whole document	1-7,23, 24,27, 28,30-33
P,X	WO 99 49029 A (GENE AUSTRALIA LIMITED AG ;GRAHAM MICHAEL WAYNE (AU); RICE ROBERT) 30 September 1999 (1999-09-30) the whole document	1-6,8, 10-13, 18,27, 28,30-33
P,X	WO 99 32619 A (CARNEGIE INST OF WASHINGTON ;MONTGOMERY MARY K (US); FIRE ANDREW () 1 July 1999 (1999-07-01) claims 1,5	1,27
A	BAULCOMBE D: "Mechanisms of pathogen-derived resistance to viruses in transgenic plants" PLANT CELL,US,AMERICAN SOCIETY OF PLANT PHYSIOLOGISTS, ROCKVILLE, MD, vol. 8, no. 10, 1 October 1996 (1996-10-01), pages 1833-1844, XP002095878 ISSN: 1040-4651 the whole document	1-33
A	WO 98 36083 A (ANGELL SUSAN MARY ;BAULCOMBE DAVID CHARLES (GB); PLANT BIOSCIENCE) 20 August 1998 (1998-08-20) the whole document	1-33
A	WO 99 15682 A (LEDERER CARSTEN WERNER ;BAULCOMBE DAVID CHARLES (GB); VOINNET OLIV) 1 April 1999 (1999-04-01) the whole document	1-33
A	WO 98 37223 A (CORNELL RES FOUNDATION INC) 27 August 1998 (1998-08-27) the whole document	1-33
A	WO 98 53083 A (LOWE ALEXANDRA LOUISE ;GRIERSON DONALD (GB); ZENECA LTD (GB); HAMI) 26 November 1998 (1998-11-26) the whole document	10-13

-/-

INTERNATIONAL SEARCH REPORT

Int'l Application No

PCT/EP 00/04117

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	MONTGOMERY M K ET AL: "Double-stranded RNA as a mediator in sequence-specific genetic silencing and co-suppression" TRENDS IN GENETICS,NL,ELSEVIER SCIENCE PUBLISHERS B.V. AMSTERDAM, vol. 14, no. 7, 1 July 1998 (1998-07-01), pages 255-258, XP004124680 ISSN: 0168-9525 the whole document	1-33
A	GRANT SARAH R: "Dissecting the mechanisms of posttranscriptional gene silencing: Divide and conquer." CELL, vol. 96, no. 3, 5 February 1999 (1999-02-05), pages 303-306, XP002146483 ISSN: 0092-8674 the whole document	1-33
A	WO 90 14090 A (HEM RES INC) 29 November 1990 (1990-11-29) page 5	25,26
P,A	WO 99 61631 A (NOVARTIS ERFINDUNGEN VERWALTUN ;NOVARTIS AG (CH); HEIFETZ PETER BE) 2 December 1999 (1999-12-02) the whole document	1-33
E	WO 00 44914 A (FARRELL MICHAEL J ;LI YIN XIONG (US); KIRBY MARGARET L (US); MEDIC) 3 August 2000 (2000-08-03) claims 1,6,7	1,27

INTERNATIONAL SEARCH REPORT

information on patent family members

International Application No

PCT/EP 00/04117

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9953050	A	21-10-1999	AU 2951499 A	01-11-1999
WO 9949029	A	30-09-1999	NONE	
WO 9932619	A	01-07-1999	AU 1938099 A	12-07-1999
WO 9836083	A	20-08-1998	AU 6001698 A EP 0970228 A	08-09-1998 12-01-2000
WO 9915682	A	01-04-1999	AU 9175198 A EP 1017831 A AU 6001698 A EP 0970228 A	12-04-1999 12-07-2000 08-09-1998 12-01-2000
WO 9837223	A	27-08-1998	AU 6657198 A CN 1252102 T EP 0970237 A	09-09-1998 03-05-2000 12-01-2000
WO 9853083	A	26-11-1998	AU 7444298 A EP 0983370 A	11-12-1998 08-03-2000
WO 9014090	A	29-11-1990	EP 0473576 A JP 4507083 T	11-03-1992 10-12-1992
WO 9961631	A	02-12-1999	AU 4368399 A	13-12-1999
WO 0044914	A	03-08-2000	NONE	